{"gene":"TFAP2C","run_date":"2026-06-10T10:51:55","timeline":{"discoveries":[{"year":2007,"finding":"TFAP2C directly binds the ERα (ESR1) promoter to activate transcription and regulates multiple estrogen signaling pathways (ERα, GPR30, FoxM1) in breast cancer cells; knockdown of TFAP2C abrogates mitogenic response to estrogen and reduces hormone-responsive tumor growth in xenografts.","method":"Chromatin immunoprecipitation (ChIP), gene knockdown (siRNA), xenograft assays, expression analysis","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP confirming direct promoter binding, siRNA knockdown with defined cellular and in vivo phenotypes, multiple orthogonal methods in a single focused study","pmids":["17875680"],"is_preprint":false},{"year":2009,"finding":"TFAP2C binding to the ERα promoter is blocked by CpG methylation and histone deacetylation; treatment with 5-aza-dC and trichostatin A restores chromatin accessibility, enabling TFAP2C and RNA Pol II binding and ERα re-expression in ERα-negative breast cancer cells.","method":"ChIP, DNA methylation analysis, chromatin accessibility assay, drug treatment (AZA/TSA)","journal":"Clinical cancer research","confidence":"High","confidence_rationale":"Tier 2 / Moderate — ChIP showing context-dependent promoter binding, chromatin accessibility assays, and pharmacologic rescue experiments in a single focused study","pmids":["19458056"],"is_preprint":false},{"year":2010,"finding":"Genome-wide ChIP-seq for TFAP2C in MCF-7 cells defined the consensus chromatin-binding sequence as SCCTSRGGS and identified 447 primary target genes including ESR1, FOXA1, GREB1, WWOX, MYC, RET, and members of the retinoic acid response pathway.","method":"ChIP-seq, expression microarray with TFAP2C knockdown","journal":"Genes, chromosomes & cancer","confidence":"High","confidence_rationale":"Tier 2 / Strong — genome-wide ChIP-seq combined with expression arrays after knockdown, rigorous identification of direct targets in a focused study","pmids":["20629094"],"is_preprint":false},{"year":2012,"finding":"TFAP2C forms a ternary complex with Myc and the H3K4me3 demethylase KDM5B at the CDKN1A (p21cip) proximal promoter; all three proteins collaborate to repress p21, requiring the AP-2 binding site at -111/-103 and KDM5B demethylase activity. The TFAP2C C-terminal 270 aa are required for Myc and KDM5B interaction. Overexpression forces S-phase entry and attenuates checkpoint activation.","method":"Co-immunoprecipitation, ChIP, luciferase reporter assay, siRNA knockdown, domain-mapping mutagenesis","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal co-IP, ChIP at endogenous locus, domain mutagenesis, functional cell cycle readouts; multiple orthogonal methods","pmids":["22371483"],"is_preprint":false},{"year":2012,"finding":"TFAP2C directly regulates GPX1 expression by binding to an AP-2 regulatory region in the GPX1 promoter; CpG methylation of this region in certain breast cancer cell lines blocks TFAP2C binding and silences GPX1, which can be reversed by 5-aza-dC treatment.","method":"ChIP-seq, siRNA knockdown, luciferase reporter assay, methylation analysis, 5-aza-dC treatment","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP-seq confirming direct binding, siRNA knockdown, epigenetic rescue experiments with multiple orthogonal methods","pmids":["22964634"],"is_preprint":false},{"year":2012,"finding":"TFAP2C directly regulates expression of the RET proto-oncogene through five AP-2 binding sites in the RET promoter (confirmed by ChIP-seq and gel-shift), independently of estrogen receptor expression.","method":"ChIP-seq, gel-shift (EMSA), siRNA knockdown, luciferase reporter assay","journal":"Annals of surgical oncology","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP-seq and EMSA confirming direct binding at multiple sites, ER-independent knockdown validation","pmids":["22878616"],"is_preprint":false},{"year":2013,"finding":"TFAP2C directly binds an AP-2 regulatory region in the ECM1 promoter (confirmed by ChIP-seq and EMSA) and regulates ECM1 expression in melanoma cells; knockdown or overexpression of TFAP2C correspondingly decreases or increases ECM1.","method":"ChIP-seq, EMSA (gel-shift), siRNA knockdown, adenoviral overexpression, luciferase reporter assay, 5' RACE","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-seq and EMSA confirming direct binding, knockdown and OE validation, single lab","pmids":["24023917"],"is_preprint":false},{"year":2013,"finding":"TFAP2C is required for murine fetal primordial germ cell (PGC) maintenance and directly binds regulatory regions of target genes including Sfrp1, Dmrt1, Nanos3, c-Kit, Cdk6, Cdkn1a, Fgf4, Klf4, Dnmt3b, and Dnmt3l (confirmed by ChIP); haploinsufficiency predisposes to teratomas on 129S2/Sv background.","method":"Global gene expression profiling (knockout mESCs and PGC-like cells), chromatin immunoprecipitation (ChIP), conditional knockout mouse model","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic loss-of-function with specific in vivo phenotype, ChIP confirming direct binding at multiple target loci, multiple orthogonal methods","pmids":["23967156"],"is_preprint":false},{"year":2014,"finding":"Knockdown of TFAP2C in luminal breast carcinoma cells induces epithelial-mesenchymal transition (loss of luminal gene expression, gain of basal gene expression). Conditional knockout of Tcfap2c in mouse mammary epithelium (MMTV-Cre) reduces CD24hi/CD49fmid luminal cell population and increases CD24mid/CD49fhi basal cell population.","method":"siRNA knockdown, conditional knockout mouse model, FACS analysis of mammary cell populations, expression profiling","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 / Strong — loss-of-function in both human cell lines and conditional knockout mouse model with defined cellular phenotype, multiple orthogonal readouts","pmids":["24469049"],"is_preprint":false},{"year":2016,"finding":"TFAP2C promotes NSCLC cell cycle progression and tumorigenesis by transcriptionally inducing oncogenic miR-183 (which blocks AKAP12-mediated cyclin D1 inhibition) and simultaneously downregulating tumor-suppressive miR-33a (resulting in CDK6 activation); validated in xenograft mouse model.","method":"Overexpression/knockdown assays, microRNA expression analysis, xenograft mouse model, cell cycle analysis","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — defined pathway via miRNA intermediaries, xenograft validation, single lab with multiple methods","pmids":["27593936"],"is_preprint":false},{"year":2016,"finding":"TFAP2C transcriptionally upregulates TGFBR1 in NSCLC cells, which activates PAK1 signaling to promote tumor cell proliferation, migration, and EMT; validated in xenograft model.","method":"Microarray analysis, overexpression/knockdown assays, xenograft model, expression analysis of patient tissue","journal":"Experimental & molecular medicine","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — pathway defined by expression and knockdown, lacks direct promoter binding confirmation (ChIP), xenograft validation provides in vivo support","pmids":["27885255"],"is_preprint":false},{"year":2016,"finding":"TFAP2C directly regulates EGFR expression in luminal breast cancer (ChIP-seq); co-knockdown of EGFR and TFAP2C target RET reduces proliferation more than either alone; vandetanib response depends on TFAP2C expression.","method":"ChIP-seq, siRNA knockdown, cell proliferation assays, xenograft assays","journal":"Molecular cancer therapeutics","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP-seq confirming direct binding, genetic epistasis via dual knockdown, in vivo xenograft validation","pmids":["26832794"],"is_preprint":false},{"year":2016,"finding":"TFAP2C regulates trophoblast proliferation and placental development by repressing Cdkn1a (p21) and Dusp6 to maintain ERK1/2 and AKT activation; loss of TFAP2C in TPBPA+ progenitors causes junctional zone growth arrest and reduced glycogen synthesis.","method":"Conditional knockout (Cre-lox), Western blot analysis of signaling pathways, gene expression analysis, knockdown in human trophoblast cell line (JAr)","journal":"Development (Cambridge, England)","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional knockout with specific cellular and signaling phenotype, validated in human cell line knockdown, multiple orthogonal methods","pmids":["26811378"],"is_preprint":false},{"year":2018,"finding":"TFAP2C is upregulated during primed-to-naive pluripotency reversion, binds naive-specific enhancers genome-wide, facilitates opening of enhancers proximal to pluripotency factors (including a naive-specific OCT4/POU5F1 enhancer), and is required to maintain naive pluripotency and repress neuroectodermal differentiation.","method":"ATAC-seq, ChIP-seq, loss-of-function (siRNA/shRNA), gain-of-function in human ESCs, reporter assays","journal":"Nature cell biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genome-wide chromatin accessibility and binding mapping (ATAC-seq + ChIP-seq) combined with functional loss/gain experiments, multiple orthogonal methods","pmids":["29695788"],"is_preprint":false},{"year":2018,"finding":"TFAP2C-bound naive enhancer at the OCT4 (POU5F1) locus is required for OCT4 expression and hPGCLC identity; CRISPR/Cas9 deletion of this enhancer impairs OCT4 expression and hPGCLC specification.","method":"ATAC-seq, CRISPR/Cas9 enhancer deletion, expression analysis in hPGCs and hPGCLCs","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 1 / Moderate — CRISPR deletion of specific enhancer with defined functional consequence, ATAC-seq chromatin mapping; single lab but rigorous","pmids":["30590035"],"is_preprint":false},{"year":2018,"finding":"TFAP2C promotes colorectal cancer stemness and chemoresistance to 5-FU by inhibiting Hippo signaling via transcriptional upregulation of ROCK1 and ROCK2.","method":"Western blot, luciferase reporter assay, ChIP, in vitro and in vivo functional assays","journal":"Journal of experimental & clinical cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and luciferase confirming direct transcriptional regulation, in vivo xenograft validation, single lab","pmids":["29439714"],"is_preprint":false},{"year":2019,"finding":"TFAP2C acts as the first transcription factor in a two-stage chromatin-remodeling cascade during epidermal differentiation: TFAP2C initiates surface ectoderm chromatin landscape and induces p63 expression and binding sites, enabling p63 to then autoregulate and mature the keratinocyte program. TFAP2C alone (not p63) is sufficient to initiate surface ectoderm differentiation.","method":"ATAC-seq, ChIP-seq, RNA-seq, overexpression of TFAP2C in human PSCs, inference regulatory network analysis, functional keratinocyte differentiation assays","journal":"Cell stem cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — genome-wide chromatin and binding analyses combined with gain-of-function experiments showing sufficiency, epistasis between TFAP2C and p63","pmids":["30686763"],"is_preprint":false},{"year":2019,"finding":"TFAP2C regulates cell collision guidance (reorientation of fibroblasts upon collision) in part by controlling expression of RND3; RND3 localizes to cell-cell collision zones and downregulates actomyosin activity there, enabling anisotropic extracellular matrix generation. Loss of TFAP2C leads to failure of cell collision guidance and isotropic matrix.","method":"Transcription factor knockdown/overexpression, live cell imaging, Vicsek modeling, RND3 localization experiments, actomyosin activity assays","journal":"Nature materials","confidence":"High","confidence_rationale":"Tier 2 / Strong — combined experimentation and mathematical modeling, RND3 localization, actomyosin functional readout, multiple orthogonal methods","pmids":["31659294"],"is_preprint":false},{"year":2019,"finding":"TFAP2C directly regulates CA12 (carbonic anhydrase XII) expression in luminal breast cancer by binding its promoter region (ChIP-seq), and also indirectly through upregulation of ERα; CA12 is epigenetically silenced in basal breast cancer by histone deacetylation and CpG methylation.","method":"ChIP-seq, siRNA knockdown, methylation analysis, TSA/5-aza-dC treatment, expression analysis in primary tumors","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-seq confirming direct binding, epigenetic rescue experiments, single lab","pmids":["31636386"],"is_preprint":false},{"year":2019,"finding":"TFAP2C increases NSCLC cell proliferation by downregulating GADD45B and PMAIP1 at both mRNA and protein levels, promoting cell cycle progression and motility.","method":"Microarray analysis, overexpression/knockdown, cell proliferation and motility assays","journal":"Biological research","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, expression-based validation without direct promoter binding confirmation","pmids":["31296259"],"is_preprint":false},{"year":2020,"finding":"TFAP2C promotes mesenchymal-to-epithelial transition (MET) during somatic cell reprogramming by directly binding epithelial gene promoters (ChIP-qPCR) to activate their expression; knockdown of E-cadherin (Cdh1), a direct TFAP2C target, antagonizes TFAP2C-mediated reprogramming. TFAP2C also inhibits c-Myc-dependent apoptosis during reprogramming.","method":"RNA-seq, ChIP-qPCR, overexpression/knockdown during iPSC reprogramming, siRNA knockdown of downstream targets","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-qPCR confirming direct binding to epithelial gene promoters, genetic epistasis via Cdh1 knockdown, single lab","pmids":["32587258"],"is_preprint":false},{"year":2020,"finding":"METTL3 m6A-methylates TFAP2C mRNA, and this modification is read by IGF2BP1; this enhances TFAP2C mRNA stability and promotes seminoma cell survival under cisplatin treatment by upregulating DNA repair-related genes.","method":"m6A sequencing, RNA immunoprecipitation (RIP), expression analysis, knockdown/overexpression","journal":"Journal of cellular and molecular medicine","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — RIP confirming m6A reader binding, mRNA stability assays, mechanistic pathway placed in context, single lab","pmids":["32857912"],"is_preprint":false},{"year":2020,"finding":"TFAP2C suppresses miR-23a-5p expression by directly binding the miR-23a promoter (ChIP assay); miR-23a-5p targets SFRP5, an inhibitor of Wnt5a; through this axis, TFAP2C inhibits autophagy to reduce cardiomyocyte H/R injury.","method":"ChIP assay, dual-luciferase reporter assay, RIP assay, overexpression/knockdown, cell viability assays","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP confirming direct promoter binding for miR-23a, multiple assays, single lab","pmids":["37191968"],"is_preprint":false},{"year":2021,"finding":"GATA3 or GATA2 combined with SOX17 and TFAP2C are sufficient to generate human PGCLCs from pluripotent cells; SOX17, TFAP2C, and BLIMP1 alone are insufficient. GATA3/GATA2 knockouts dose-dependently impair BMP-induced hPGCLC specification, while GATA3/GATA2 expression is unaffected by SOX17, TFAP2C, or BLIMP1 knockouts—placing GATA3/GATA2 upstream of or parallel to SOX17/TFAP2C in BMP signaling.","method":"Transcription factor overexpression in human PSCs, gene knockout (siRNA/shRNA), hPGCLC induction assays, xenogeneic ovary reconstitution","journal":"Life science alliance","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis combined with sufficiency experiments (TF-induced hPGCLCs) and functional in vivo reconstitution; multiple orthogonal methods","pmids":["33608411"],"is_preprint":false},{"year":2021,"finding":"TFAP2C physically interacts with Arid4b (a Sin3a corepressor complex member) in mouse ESCs, identified by endogenous co-immunoprecipitation and proximity ligation assay; this interaction is linked to repression of a subset of Tfap2c-regulated genes during meso/endoderm differentiation.","method":"Co-immunoprecipitation (endogenous), proximity ligation assay (PLA), ChIP (H3K27Ac), differentiation assays","journal":"Turkish journal of biology","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — endogenous co-IP confirmed by PLA, but functional link to repression inferred; single lab, single paper","pmids":["33907498"],"is_preprint":false},{"year":2022,"finding":"TFAP2C transcriptionally activates PCAT1 lncRNA expression in prostate cancer cells; PCAT1 then inhibits ferroptosis through c-Myc/miR-25-3p/SLC7A11 signaling to promote docetaxel resistance.","method":"ChIP assay, luciferase reporter assay, RNA sequencing, overexpression/knockdown, ferroptosis assays","journal":"Frontiers in oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and luciferase confirming direct transcriptional activation of PCAT1, functional ferroptosis readouts, single lab","pmids":["35402284"],"is_preprint":false},{"year":2023,"finding":"TFAP2C targets the pri-miRNA-132 gene in dorsal root ganglion neurons and represses miR-132-5p expression; exosomal TFAP2C (from fibroblasts) is transferred into axons where it promotes axon regeneration via the miR-132-5p/CAMKK1 axis.","method":"ChIP assay (TFAP2C binding to pri-miRNA-132), exosome isolation and proteomic identification, miRNA expression analysis, axon regeneration assays in vitro and in vivo (rat sciatic nerve model)","journal":"Bioactive materials","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP confirming direct binding to miRNA gene, functional in vivo nerve regeneration readout, single lab","pmids":["36936807"],"is_preprint":false},{"year":2024,"finding":"In totipotent mouse embryos, TFAP2C acts as a 'bipotency activator' by binding and activating both early TE and ICM lineage genes at the 2–8-cell stages; upon trophoblast commitment, TFAP2C leaves ICM gene loci and co-occupies late TE genes with CDX2, then extra-embryonic ectoderm genes with SOX2. Tfap2c deficiency downregulates both early ICM genes (Nanog, Nr5a2, Tdgf1) and early TE genes (Tfeb, Itgb5), and increases ICM apoptosis.","method":"uliCUT&RUN-seq (in vivo TF binding), embryo Tfap2c knockout, expression analysis at multiple developmental stages","journal":"Nature structural & molecular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genome-wide TF binding in vivo using uliCUT&RUN-seq combined with loss-of-function in embryos and multi-stage developmental readouts; replicated across two Nature Struct Mol Biol papers (38243114, 38789684)","pmids":["38243114"],"is_preprint":false},{"year":2024,"finding":"TFAP2C and TEAD4 together accelerate loss of totipotency and promote lineage diversification by establishing a bistable switch; they paradoxically activate both TE specifiers and ICM specifiers in bipotent cells, with asymmetric apical domain segregation resolving this into Hippo-OFF (TE) or Hippo-ON (ICM) fates. TFAP2C activates specifiers of both ICM and TE fate.","method":"Overexpression and loss-of-function of TFAP2C and TEAD4 in mouse embryos, Hippo signaling readouts, live imaging of apical domain, lineage marker analysis","journal":"Nature structural & molecular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic gain/loss-of-function in embryos with mechanistic Hippo signaling readouts, consistent with independent data from PMID 38243114","pmids":["38789684"],"is_preprint":false},{"year":2024,"finding":"TFAP2C binds to the Sox2 proximal promoter in mouse preimplantation embryos to activate Sox2 transcription; TFAP2C and Hippo signaling cooperatively regulate Sox2 expression.","method":"ChIP/CUT&RUN in embryos, loss-of-function via TFAP2C knockdown/knockout, cis-regulatory element deletion, Sox2 expression analysis","journal":"Development (Cambridge, England)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct binding to Sox2 promoter confirmed, functional cooperation with Hippo pathway demonstrated, single lab","pmids":["40600821"],"is_preprint":false},{"year":2024,"finding":"TFAP2C defines a regulatory network in murine peri-implantation embryos involving TEAD4 and KLF5; maternal retinoic acid metabolism regulates TFAP2C expression and function via active demethylation of SINEs (RARG-TFAP2C-TEAD4/KLF5 axis); both genomic imprinting and SNPs influence TF positioning through TFAP2C.","method":"uliCUT&RUN-seq (genome-wide TF binding), TFAP2C loss-of-function, retinoic acid pathway manipulation, promoter-enhancer interaction analysis","journal":"Developmental cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genome-wide binding combined with genetic and metabolic perturbations, single lab","pmids":["38574734"],"is_preprint":false},{"year":2024,"finding":"TFAP2C transcriptionally activates CST1 (cystatin SN) expression by binding its promoter (dual-luciferase and ChIP assay); TFAP2C/CST1 axis promotes breast cancer cell proliferation and suppresses ferroptosis (GPX4-dependent).","method":"Dual-luciferase reporter assay, ChIP, siRNA knockdown, overexpression, cell cycle/apoptosis/ferroptosis assays, xenograft model","journal":"Biochemical genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and luciferase confirming direct promoter binding, functional ferroptosis and proliferation readouts, in vivo validation, single lab","pmids":["38243003"],"is_preprint":false},{"year":2024,"finding":"TFAP2C transcriptionally activates DDR1 in palbociclib-resistant breast cancer cells; inhibition of TFAP2C re-sensitizes resistant cells to palbociclib. TFAP2C-DDR1 gene signatures are enriched in patients after palbociclib treatment.","method":"Quantitative high-throughput combination screening, genomics/proteomics, siRNA knockdown, xenograft model, GSEA of clinical data","journal":"Cancer letters","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — transcriptional regulation inferred from expression and knockdown without direct ChIP confirmation cited in abstract; xenograft validation provides in vivo support; single lab","pmids":["39603379"],"is_preprint":false},{"year":2024,"finding":"TFAP2C transcriptionally activates FLT3 expression (confirmed by dual-luciferase and ChIP); the TFAP2C/FLT3 axis inhibits ferroptosis in breast cancer by suppressing mitochondrial autophagy.","method":"Dual-luciferase reporter assay, ChIP, knockdown/overexpression, autophagy and ferroptosis assays","journal":"The international journal of biochemistry & cell biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and luciferase confirming direct transcriptional activation, functional ferroptosis/autophagy readouts, single lab","pmids":["39536858"],"is_preprint":false},{"year":2024,"finding":"TFAP2C directly binds the YAP promoter to activate its transcription (dual-luciferase and ChIP); TFAP2C promotes cisplatin resistance in bladder cancer through YAP upregulation and downstream β-catenin pathway activation.","method":"Dual-luciferase reporter assay, ChIP, siRNA knockdown, xenograft model","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and luciferase confirming direct promoter binding, in vivo xenograft validation, single lab","pmids":["40541807"],"is_preprint":false},{"year":2024,"finding":"Knockdown of UBA2 (SUMO activating enzyme) increases TFAP2C binding to enhancers genome-wide (not due to TFAP2C SUMOylation itself); TFAP2C recruits HDAC1 to chromatin, and TFAP2C knockdown reduces HDAC1 binding and increases H3K27Ac at enhancers, indicating TFAP2C is required for HDAC machinery recruitment to suppress enhancer activity.","method":"ChIP-seq (UBA2 KD and TFAP2C KD), proteomics of TFAP2C interactome on chromatin, molecular biology (ChIP for HDAC1), SUMOylation inhibitor","journal":"Research square (preprint)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-seq and proteomics of chromatin-bound TFAP2C interactome, multiple orthogonal methods, but preprint status warrants caution","pmids":["38645262"],"is_preprint":true},{"year":2024,"finding":"TFAP2C is required for invasive trophoblast cell-specific functions in rat hemochorial placentation; conditional (Cre-lox) invasive trophoblast-specific disruption of Tfap2c inhibits intrauterine trophoblast invasion and causes intrauterine and postnatal growth restriction. Homozygous global disruption is prenatally lethal. Monoallelic conditional disruption does not impair invasion, indicating gene dosage dependence.","method":"CRISPR/Cas9 global genome editing, Cre-lox conditional mutagenesis, histological analysis of placentation site, growth measurements","journal":"JCI insight","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell type-specific conditional knockout with defined in vivo phenotype, dosage-sensitivity established by monoallelic vs biallelic comparison; confirmed in two publications (peer-reviewed and preprint: 39625795, 39554130)","pmids":["39625795","39554130"],"is_preprint":false},{"year":2024,"finding":"TFAP2C directly binds the STEAP3 promoter and positively regulates its expression (ChIP and luciferase); TFAP2C/STEAP3 axis activates β-catenin signaling to promote lung squamous cell carcinoma progression.","method":"ChIP assay, luciferase reporter assay, siRNA knockdown, overexpression, in vivo xenograft model","journal":"Biology direct","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and luciferase confirming direct promoter binding, in vivo validation, single lab","pmids":["39716275"],"is_preprint":false},{"year":2025,"finding":"TFAP2C binds to the KEAP1 promoter and recruits HDAC1/2, leading to H3K27 deacetylation and transcriptional repression of KEAP1; reduced KEAP1 stabilizes NRF2 protein, activating NRF2-dependent antioxidant transcription and conferring ferroptosis resistance in ovarian cancer.","method":"ChIP assay, dual-luciferase reporter assay, knockdown/overexpression, ROS/Fe2+/lipid peroxidation assays, mitochondrial membrane potential assay, rescue experiments","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP confirming TFAP2C binding to KEAP1 promoter with HDAC1/2 recruitment, epigenetic mechanism defined, single lab","pmids":["41703284"],"is_preprint":false},{"year":2025,"finding":"E2F1 activates TFAP2C transcription by binding to its promoter, and the resulting E2F1-TFAP2C-SOX17 positive-feedback loop controls human germline stem cell fate (hPGCLC identity) in organoids from Turner syndrome iPSCs; E2F1 knockout impairs hPGCLC specification.","method":"Single-cell transcriptomics, organoid differentiation system, ChIP (E2F1 binding to TFAP2C promoter), E2F1 knockout, expression analysis","journal":"Cell & bioscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP confirming direct E2F1 binding to TFAP2C promoter, genetic knockout, single lab","pmids":["41035077"],"is_preprint":false},{"year":2025,"finding":"TFAP2C deletion is synthetic viable with HNRNPK depletion in glioma cells; HNRNPK depletion inhibits mTORC1 and increases prion propagation; TFAP2C overexpression enhances mTORC1 downstream functions. Co-deletion of TFAP2C with HNRNPK restores mTORC1 activity and reverses prion elevation, establishing epistatic interaction between TFAP2C, HNRNPK, and mTORC1 in metabolic and prion regulation.","method":"Synthetic-viability CRISPR screen, mTOR signaling assays, metabolic assays (ATP, autophagy), prion propagation assays, genetic epistasis","journal":"PLoS pathogens","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — CRISPR screen establishing genetic interaction, mTORC1 signaling readouts, prion functional assay; epistatic relationship defined, single lab","pmids":["42008486"],"is_preprint":false},{"year":2025,"finding":"TFAP2C directly binds the TFAP2C promoter region and activates TFAP2C transcription in response to PART1/miR-302a-3p signaling; TFAP2C directly binds the DUSP5 promoter to activate DUSP5 expression, thereby suppressing autophagy and apoptosis in H/R-injured cardiomyocytes.","method":"Dual-luciferase reporter assay, ChIP assay, siRNA knockdown, flow cytometry, TUNEL, MIRI mouse model","journal":"Korean circulation journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and luciferase confirming direct binding to DUSP5 promoter, in vivo MIRI model validation, single lab","pmids":["38654453"],"is_preprint":false},{"year":2025,"finding":"TFAP2C directly binds to the PI3K promoter and activates its transcription (confirmed by ChIP and luciferase); through this mechanism TFAP2C activates the PI3K/AKT/mTOR pathway to promote EMT and proliferation in glioblastoma.","method":"ChIP assay, dual-luciferase reporter assay, siRNA knockdown, co-overexpression rescue, xenograft model","journal":"Cell biology international","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and luciferase confirming direct promoter binding, in vivo xenograft validation, single lab","pmids":["40667743"],"is_preprint":false},{"year":2026,"finding":"TFAP2C directly binds the VEGFA promoter to transcriptionally activate VEGFA expression in endothelial cells, facilitating VEGFA/VEGFR2-dependent angiogenesis; propofol suppresses this by activating ER stress (PERK/eIF2α phosphorylation) to reduce TFAP2C translation.","method":"ChIP assay, luciferase reporter assay, propofol treatment with ER stress pathway analysis, in vitro angiogenesis assays, in vivo angiogenesis model","journal":"Apoptosis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and luciferase confirming direct binding to VEGFA promoter, pharmacologic mechanism defined, single lab","pmids":["41524974"],"is_preprint":false},{"year":2006,"finding":"In zebrafish, tfap2c (encoding AP-2 gamma) is expressed transiently in neural crest and non-neural ectoderm; simultaneous morpholino-knockdown of tfap2a and tfap2c completely prevents neural crest induction (epistasis showing redundancy), and reduces cranial placode derivatives. Single tfap2c knockdown alone shows no visible developmental defect.","method":"Antisense morpholino knockdown (single and double), transplant studies (cell autonomy), in situ hybridization, neural crest marker analysis in zebrafish embryos","journal":"Developmental biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis through double knockdown demonstrating redundancy and cell-autonomous function, transplant experiments, focused developmental study","pmids":["17258188"],"is_preprint":false},{"year":2006,"finding":"AP-2 gamma (TFAP2C ortholog) binds a specific enhancer element (FP2 DNase I-protected region) in the rat placental lactogen II (rPLII) gene 5' flanking region in trophoblast cells; this binding was confirmed by gel-shift assay with AP-2 gamma-specific antiserum and chromatin immunoprecipitation in Rcho giant cells; AP-2 gamma transactivates the enhancer in cotransfection assays.","method":"Protein purification by DNA affinity, HPLC-MALDI-TOF mass spectrometry identification, gel-shift assay (EMSA), ChIP, cotransfection luciferase assay","journal":"Endocrinology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro biochemical binding confirmed by EMSA, in vivo occupancy by ChIP, transactivation by luciferase; multiple orthogonal methods in single study","pmids":["16794002"],"is_preprint":false},{"year":2025,"finding":"TFAP2C directly binds the TFAP2C (proximal) promoter region and activates PTGES transcription in lung adenocarcinoma cells (confirmed by ChIP and dual-luciferase); PTGES promotes gefitinib resistance through NOTCH3 signaling, and TFAP2C knockdown-mediated loss of PTGES is reversed by PTGES overexpression.","method":"ChIP assay, dual-luciferase reporter assay, GSEA, knockdown/overexpression in PC-9/GR cells, NOTCH3 inhibitor rescue","journal":"Journal of clinical biochemistry and nutrition","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and luciferase confirming direct binding to PTGES promoter, pathway defined through NOTCH3 inhibitor, single lab","pmids":["40777819"],"is_preprint":false}],"current_model":"TFAP2C is a sequence-specific AP-2 family transcription factor that binds a SCCTSRGGS consensus element to directly activate or repress hundreds of target genes; it regulates pluripotency (maintaining naive human ESC state by opening enhancers near OCT4 and other factors), primordial germ cell specification and maintenance, trophoblast lineage commitment and invasive trophoblast function (essential for placentation), epidermal differentiation (by priming chromatin for subsequent p63 action), and luminal breast cancer identity (through direct regulation of ESR1/ERα, FOXA1, EGFR, RET, GPX1, CA12, and others); it represses CDKN1A (p21) via a ternary complex with Myc and the demethylase KDM5B; its activity at target promoters is gated by CpG methylation and histone deacetylation status; and it regulates cell collision guidance (via RND3/actomyosin) and axon regeneration (via miR-132-5p/CAMKK1), while interacting physically with the Sin3a complex member Arid4b and recruiting HDAC machinery to enhancers."},"narrative":{"mechanistic_narrative":"TFAP2C is a sequence-specific AP-2 family transcription factor that recognizes the SCCTSRGGS consensus element and directly activates or represses several hundred target genes to control lineage specification, pluripotency, and proliferative programs [PMID:20629094]. In early development it functions as a master regulator of cell-fate decisions: in totipotent mouse embryos it acts as a 'bipotency activator' that binds and activates both inner-cell-mass and trophectoderm genes, then resolves fate by partitioning between CDX2- and SOX2-bound loci, cooperating with TEAD4 and Hippo signaling to establish a bistable lineage switch [PMID:38243114, PMID:38789684, PMID:40600821]. It is required for primordial germ cell maintenance and, together with SOX17 and GATA factors, is sufficient to drive human PGC-like cell specification, in part through a TFAP2C-bound enhancer at the OCT4/POU5F1 locus [PMID:23967156, PMID:30590035, PMID:33608411]; it also maintains naive human pluripotency by opening enhancers near pluripotency genes [PMID:29695788]. In differentiating tissues TFAP2C initiates the surface-ectoderm chromatin landscape and induces p63 to launch the keratinocyte program [PMID:30686763], and it is essential for trophoblast proliferation and invasive trophoblast function during placentation, where loss causes growth restriction and lethality in a gene-dosage-dependent manner [PMID:26811378, PMID:39625795, PMID:39554130]. As a transcriptional regulator it both activates targets and recruits corepressor machinery: it forms a ternary complex with Myc and the demethylase KDM5B to repress CDKN1A (p21) and drive S-phase entry [PMID:22371483], physically associates with the Sin3a-complex member Arid4b [PMID:33907498], and recruits HDAC1/2 to enhancers and promoters to deacetylate H3K27 and suppress transcription [PMID:38645262, PMID:41703284]. In breast cancer it establishes and maintains luminal identity through direct regulation of ESR1/ERα, FOXA1, EGFR, RET, GPX1, and CA12, with binding at these targets gated by CpG methylation and histone deacetylation [PMID:17875680, PMID:19458056, PMID:20629094, PMID:22964634, PMID:22878616, PMID:26832794, PMID:31636386]. Across diverse cancers TFAP2C activates oncogenic programs and confers therapy resistance, frequently by suppressing ferroptosis or activating PI3K/AKT, β-catenin, and NRF2 pathways through direct target activation [PMID:38243003, PMID:39536858, PMID:40541807, PMID:41703284, PMID:40667743].","teleology":[{"year":2006,"claim":"Established that the AP-2 gamma factor binds and transactivates a defined enhancer in a trophoblast gene, providing the first direct biochemical evidence of its sequence-specific transcriptional activity.","evidence":"DNA-affinity purification, mass-spec identification, EMSA, ChIP and luciferase on the rat placental lactogen II enhancer in trophoblast cells","pmids":["16794002"],"confidence":"High","gaps":["Single target gene; genome-wide binding repertoire undefined","Mammalian developmental requirement not yet tested"]},{"year":2006,"claim":"Demonstrated through genetic epistasis that tfap2c functions redundantly with tfap2a in neural crest induction, indicating an early ectodermal patterning role masked by paralog redundancy.","evidence":"Single and double antisense morpholino knockdown with transplant cell-autonomy tests in zebrafish embryos","pmids":["17258188"],"confidence":"High","gaps":["Single knockdown shows no phenotype, leaving non-redundant functions unresolved","Direct target genes in neural crest not mapped"]},{"year":2007,"claim":"Identified TFAP2C as a direct activator of the ERα promoter that drives estrogen-dependent breast cancer growth, defining its role in hormone-responsive tumor biology.","evidence":"ChIP, siRNA knockdown, and xenograft assays in breast cancer cells","pmids":["17875680"],"confidence":"High","gaps":["Did not address why binding is restricted to certain cell contexts","Broader target set unknown"]},{"year":2009,"claim":"Showed that TFAP2C promoter occupancy is epigenetically gated, explaining context-dependent target activation in ERα-positive versus negative tumors.","evidence":"ChIP, methylation analysis, chromatin accessibility assays, and AZA/TSA pharmacologic rescue in breast cancer cells","pmids":["19458056"],"confidence":"High","gaps":["Mechanism linking methylation to loss of binding affinity not resolved structurally","Generality across other targets initially untested"]},{"year":2010,"claim":"Defined the genome-wide TFAP2C binding consensus and primary target set, converting it from a single-gene regulator to a network hub controlling estrogen and growth-factor signaling.","evidence":"ChIP-seq plus expression arrays after knockdown in MCF-7 cells","pmids":["20629094"],"confidence":"High","gaps":["Direct versus indirect effects not fully separated for all 447 targets","Cofactor requirements for activation vs repression unaddressed"]},{"year":2012,"claim":"Revealed a repressive mechanism in which TFAP2C nucleates a ternary complex with Myc and KDM5B to silence p21 and drive cell-cycle progression, establishing it as a corepressor-recruiting factor as well as an activator.","evidence":"Reciprocal co-IP, endogenous ChIP, domain-mapping mutagenesis and cell-cycle readouts","pmids":["22371483"],"confidence":"High","gaps":["Structural basis of the ternary complex unknown","Whether this complex operates at other loci untested"]},{"year":2012,"claim":"Expanded the direct target repertoire to GPX1 and the RET proto-oncogene, with GPX1 again gated by CpG methylation, reinforcing the epigenetically controlled, ER-independent regulatory program.","evidence":"ChIP-seq, EMSA, luciferase reporters, knockdown and 5-aza-dC rescue in breast cancer cells","pmids":["22964634","22878616"],"confidence":"High","gaps":["Functional consequence of each target on tumor phenotype not fully dissected"]},{"year":2013,"claim":"Established TFAP2C as essential for primordial germ cell maintenance through direct regulation of germ-cell and DNA-methylation machinery genes, linking it to germline development and teratoma predisposition.","evidence":"Conditional knockout mouse, expression profiling, and ChIP at multiple germline target loci","pmids":["23967156"],"confidence":"High","gaps":["Cofactors directing germline-specific binding not identified","Mechanism of teratoma predisposition incompletely defined"]},{"year":2014,"claim":"Showed TFAP2C maintains luminal breast epithelial identity, with loss driving EMT and a basal cell-state shift in vivo, defining its role in epithelial lineage fidelity.","evidence":"siRNA knockdown, conditional knockout mammary mouse model, and FACS of mammary populations","pmids":["24469049"],"confidence":"High","gaps":["Direct targets enforcing luminal identity not enumerated here","Reversibility of the state shift untested"]},{"year":2016,"claim":"Defined TFAP2C-driven trophoblast and placental development via repression of Cdkn1a and Dusp6 to sustain ERK/AKT signaling, and a parallel role driving EGFR/RET dependency in luminal breast cancer.","evidence":"Conditional knockout, signaling Westerns, human trophoblast knockdown, ChIP-seq and dual-knockdown epistasis with xenografts","pmids":["26811378","26832794"],"confidence":"High","gaps":["Whether placental and tumor programs share cofactors unknown"]},{"year":2018,"claim":"Established TFAP2C as a pioneer-like enhancer-opening factor for naive pluripotency and germ-cell identity, with a specific OCT4 enhancer required for hPGCLC specification.","evidence":"ATAC-seq, ChIP-seq, loss/gain-of-function in human ESCs, and CRISPR enhancer deletion","pmids":["29695788","30590035"],"confidence":"High","gaps":["Whether TFAP2C acts as a true pioneer factor on nucleosomal DNA not directly shown","Recruited remodelers unidentified"]},{"year":2019,"claim":"Positioned TFAP2C as the initiating factor in a two-stage epidermal differentiation cascade, sufficient to launch surface-ectoderm fate and induce p63, and identified a non-developmental role in cell-collision guidance via RND3.","evidence":"ATAC-seq, ChIP-seq, RNA-seq and gain-of-function in human PSCs; live imaging and actomyosin assays for collision guidance","pmids":["30686763","31659294"],"confidence":"High","gaps":["How TFAP2C primes chromatin ahead of p63 mechanistically unresolved","Direct vs indirect control of RND3 not fully separated"]},{"year":2021,"claim":"Placed TFAP2C within the germline specification hierarchy downstream of GATA factors and identified its physical association with the Sin3a corepressor component Arid4b, connecting its repressive activity to a defined corepressor complex.","evidence":"TF sufficiency and knockout epistasis for hPGCLC induction; endogenous co-IP and PLA for Arid4b interaction","pmids":["33608411","33907498"],"confidence":"High","gaps":["Arid4b interaction confidence is Medium and functional link to repression inferred","Direct contacts within the Sin3a complex not mapped"]},{"year":2024,"claim":"Defined TFAP2C as a bipotency/bistability activator in totipotent embryos that paradoxically activates both ICM and TE specifiers and, with TEAD4 and Hippo signaling, resolves the first lineage decision.","evidence":"uliCUT&RUN-seq, embryo knockout, gain/loss-of-function and Hippo/apical-domain readouts; direct Sox2 promoter binding shown","pmids":["38243114","38789684","40600821","38574734"],"confidence":"High","gaps":["How the same factor activates opposing fate programs at distinct loci mechanistically unclear","Cofactor switching between CDX2 and SOX2 partners not fully explained"]},{"year":2024,"claim":"Demonstrated TFAP2C is required cell-autonomously for invasive trophoblast function in hemochorial placentation in a strict gene-dosage manner, with biallelic loss prenatally lethal.","evidence":"CRISPR global editing and invasive-trophoblast-specific Cre-lox conditional knockout with histology and growth measurements in rat","pmids":["39625795","39554130"],"confidence":"High","gaps":["Direct invasion-program targets not enumerated","Basis of dosage sensitivity unresolved"]},{"year":2024,"claim":"Identified an enhancer-suppressive mechanism in which TFAP2C recruits HDAC1 to chromatin to limit enhancer H3K27 acetylation, with SUMO machinery modulating its genome-wide occupancy.","evidence":"ChIP-seq under UBA2 and TFAP2C knockdown plus chromatin interactome proteomics (preprint)","pmids":["38645262"],"confidence":"Medium","gaps":["Preprint status warrants caution","Mechanism by which UBA2/SUMO controls TFAP2C binding indirect and undefined"]},{"year":2025,"claim":"Extended the HDAC-recruitment model to direct promoter repression of KEAP1, linking TFAP2C to NRF2-dependent antioxidant defense and ferroptosis resistance, consolidating its role as a recurrent suppressor of ferroptosis across cancers.","evidence":"ChIP, luciferase, HDAC1/2 recruitment analysis, and ferroptosis/redox assays in ovarian cancer cells","pmids":["41703284"],"confidence":"Medium","gaps":["Whether KEAP1 repression uses the same Sin3a/HDAC complex as enhancer suppression untested","Generality across the multiple reported ferroptosis-resistance targets not unified"]},{"year":null,"claim":"How a single factor switches between activating and HDAC-mediated repressive outputs at different loci, and what cofactors and chromatin features dictate this choice, remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural model of TFAP2C cofactor complexes","Determinants directing activator vs repressor mode at a given target undefined","Pioneer activity on nucleosomal DNA not directly demonstrated"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[2,3,5,27,45]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,2,3,13,16,27]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[3,35,38]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[2,3,27,35]},{"term_id":"GO:0000228","term_label":"nuclear chromosome","supporting_discovery_ids":[13,16,35]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,2,3,27]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[7,13,16,23,27,36,44]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[13,16,35,38]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[3,9,12]},{"term_id":"R-HSA-1474165","term_label":"Reproduction","supporting_discovery_ids":[7,14,23,39]}],"complexes":["Sin3a corepressor complex (via Arid4b)","TFAP2C-Myc-KDM5B ternary complex"],"partners":["MYC","KDM5B","ARID4B","TEAD4","SOX17","CDX2","HDAC1","KLF5"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q92754","full_name":"Transcription factor AP-2 gamma","aliases":["Activating enhancer-binding protein 2 gamma","Transcription factor ERF-1"],"length_aa":450,"mass_kda":49.2,"function":"Sequence-specific DNA-binding transcription factor that interacts with cellular enhancer elements to regulate transcription of selected genes, and which plays a key role in early embryonic development (PubMed:11694877, PubMed:24413532). AP-2 factors bind to the consensus sequence 5'-GCCNNNGGC-3' and activate genes involved in a large spectrum of important biological functions (PubMed:11694877, PubMed:24413532). TFAP2C plays a key role in early embryonic development by regulating both inner cell mass (ICM) and trophectoderm differentiation (By similarity). At the 8-cell stage, during morula development, controls expression of cell-polarity genes (By similarity). Upon trophoblast commitment, binds to late trophectoderm genes in blastocysts together with CDX2, and later to extra-embryonic ectoderm genes together with SOX2 (By similarity). Binds to both closed and open chromatin with other transcription factors (By similarity). Involved in the MTA1-mediated epigenetic regulation of ESR1 expression in breast cancer (PubMed:24413532)","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q92754/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TFAP2C","classification":"Not Classified","n_dependent_lines":71,"n_total_lines":1208,"dependency_fraction":0.058774834437086095},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/TFAP2C","total_profiled":1310},"omim":[{"mim_id":"614431","title":"VENTRICULAR SEPTAL DEFECT 2; VSD2","url":"https://www.omim.org/entry/614431"},{"mim_id":"613420","title":"POTASSIUM CHANNEL TETRAMERIZATION DOMAIN-CONTAINING PROTEIN 1; KCTD1","url":"https://www.omim.org/entry/613420"},{"mim_id":"611781","title":"PR DOMAIN-CONTAINING PROTEIN 14; PRDM14","url":"https://www.omim.org/entry/611781"},{"mim_id":"607937","title":"NANOG HOMEOBOX; NANOG","url":"https://www.omim.org/entry/607937"},{"mim_id":"606061","title":"T-BOX TRANSCRIPTION FACTOR 20; TBX20","url":"https://www.omim.org/entry/606061"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"esophagus","ntpm":27.5},{"tissue":"skin 1","ntpm":50.3}],"url":"https://www.proteinatlas.org/search/TFAP2C"},"hgnc":{"alias_symbol":["AP2-GAMMA","ERF1","TFAP2G","hAP-2g"],"prev_symbol":[]},"alphafold":{"accession":"Q92754","domains":[{"cath_id":"-","chopping":"222-299","consensus_level":"high","plddt":90.8847,"start":222,"end":299},{"cath_id":"-","chopping":"308-427","consensus_level":"high","plddt":94.8213,"start":308,"end":427}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q92754","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q92754-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q92754-F1-predicted_aligned_error_v6.png","plddt_mean":66.31},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TFAP2C","jax_strain_url":"https://www.jax.org/strain/search?query=TFAP2C"},"sequence":{"accession":"Q92754","fasta_url":"https://rest.uniprot.org/uniprotkb/Q92754.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q92754/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q92754"}},"corpus_meta":[{"pmid":"21468029","id":"PMC_21468029","title":"microRNA-214 contributes to melanoma tumour progression through suppression of TFAP2C.","date":"2011","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/21468029","citation_count":216,"is_preprint":false},{"pmid":"29695788","id":"PMC_29695788","title":"TFAP2C regulates transcription in human naive pluripotency by opening enhancers.","date":"2018","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/29695788","citation_count":147,"is_preprint":false},{"pmid":"17258188","id":"PMC_17258188","title":"Redundant activities of Tfap2a and Tfap2c are required for neural crest induction and development of other non-neural ectoderm derivatives in zebrafish embryos.","date":"2006","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/17258188","citation_count":121,"is_preprint":false},{"pmid":"29439714","id":"PMC_29439714","title":"TFAP2C promotes stemness and chemotherapeutic resistance in colorectal cancer via inactivating hippo signaling pathway.","date":"2018","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/29439714","citation_count":90,"is_preprint":false},{"pmid":"35402284","id":"PMC_35402284","title":"TFAP2C-Mediated lncRNA PCAT1 Inhibits Ferroptosis in Docetaxel-Resistant Prostate Cancer Through c-Myc/miR-25-3p/SLC7A11 Signaling.","date":"2022","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/35402284","citation_count":89,"is_preprint":false},{"pmid":"30686763","id":"PMC_30686763","title":"TFAP2C- and p63-Dependent Networks Sequentially Rearrange Chromatin Landscapes to Drive Human Epidermal Lineage Commitment.","date":"2019","source":"Cell stem cell","url":"https://pubmed.ncbi.nlm.nih.gov/30686763","citation_count":85,"is_preprint":false},{"pmid":"31659294","id":"PMC_31659294","title":"Extracellular matrix anisotropy is determined by TFAP2C-dependent regulation of cell collisions.","date":"2019","source":"Nature materials","url":"https://pubmed.ncbi.nlm.nih.gov/31659294","citation_count":84,"is_preprint":false},{"pmid":"17875680","id":"PMC_17875680","title":"TFAP2C controls hormone response in breast cancer cells through multiple pathways of estrogen signaling.","date":"2007","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/17875680","citation_count":71,"is_preprint":false},{"pmid":"20629094","id":"PMC_20629094","title":"Identification of primary gene targets of TFAP2C in hormone responsive breast carcinoma cells.","date":"2010","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/20629094","citation_count":70,"is_preprint":false},{"pmid":"22371483","id":"PMC_22371483","title":"Histone demethylase KDM5B collaborates with TFAP2C and Myc to repress the cell cycle inhibitor p21(cip) (CDKN1A).","date":"2012","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/22371483","citation_count":68,"is_preprint":false},{"pmid":"30590035","id":"PMC_30590035","title":"The TFAP2C-Regulated OCT4 Naive Enhancer Is Involved in Human Germline Formation.","date":"2018","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/30590035","citation_count":68,"is_preprint":false},{"pmid":"22560121","id":"PMC_22560121","title":"The role of transcription factor Tcfap2c/TFAP2C in trophectoderm development.","date":"2012","source":"Reproductive biomedicine online","url":"https://pubmed.ncbi.nlm.nih.gov/22560121","citation_count":62,"is_preprint":false},{"pmid":"29615098","id":"PMC_29615098","title":"MiR-10a-5p targets TFAP2C to promote gemcitabine resistance in pancreatic ductal adenocarcinoma.","date":"2018","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/29615098","citation_count":62,"is_preprint":false},{"pmid":"24469049","id":"PMC_24469049","title":"TFAP2C governs the luminal epithelial phenotype in mammary development and carcinogenesis.","date":"2014","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/24469049","citation_count":60,"is_preprint":false},{"pmid":"30771618","id":"PMC_30771618","title":"TFAP2C-Activated MALAT1 Modulates the Chemoresistance of Docetaxel-Resistant Lung Adenocarcinoma Cells.","date":"2019","source":"Molecular therapy. Nucleic acids","url":"https://pubmed.ncbi.nlm.nih.gov/30771618","citation_count":57,"is_preprint":false},{"pmid":"32857912","id":"PMC_32857912","title":"METTL3 potentiates resistance to cisplatin through m6 A modification of TFAP2C in seminoma.","date":"2020","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32857912","citation_count":56,"is_preprint":false},{"pmid":"27593936","id":"PMC_27593936","title":"TFAP2C promotes lung tumorigenesis and aggressiveness through miR-183- and miR-33a-mediated cell cycle regulation.","date":"2016","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/27593936","citation_count":55,"is_preprint":false},{"pmid":"18825690","id":"PMC_18825690","title":"Overexpression of TFAP2C in invasive breast cancer correlates with a poorer response to anti-hormone therapy and reduced patient survival.","date":"2009","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/18825690","citation_count":53,"is_preprint":false},{"pmid":"27885255","id":"PMC_27885255","title":"TFAP2C-mediated upregulation of TGFBR1 promotes lung tumorigenesis and epithelial-mesenchymal transition.","date":"2016","source":"Experimental & molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27885255","citation_count":52,"is_preprint":false},{"pmid":"33608411","id":"PMC_33608411","title":"GATA transcription factors, SOX17 and TFAP2C, drive the human germ-cell specification program.","date":"2021","source":"Life science alliance","url":"https://pubmed.ncbi.nlm.nih.gov/33608411","citation_count":51,"is_preprint":false},{"pmid":"28610956","id":"PMC_28610956","title":"Upregulation of microRNA-137 expression by Slug promotes tumor invasion and metastasis of non-small cell lung cancer cells through suppression of TFAP2C.","date":"2017","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/28610956","citation_count":51,"is_preprint":false},{"pmid":"25569170","id":"PMC_25569170","title":"A discrete transition zone organizes the topological and regulatory autonomy of the adjacent tfap2c and bmp7 genes.","date":"2015","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25569170","citation_count":49,"is_preprint":false},{"pmid":"22964634","id":"PMC_22964634","title":"Transcriptional regulation of the GPX1 gene by TFAP2C and aberrant CpG methylation in human breast cancer.","date":"2012","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/22964634","citation_count":48,"is_preprint":false},{"pmid":"31296259","id":"PMC_31296259","title":"TFAP2C increases cell proliferation by downregulating GADD45B and PMAIP1 in non-small cell lung cancer cells.","date":"2019","source":"Biological research","url":"https://pubmed.ncbi.nlm.nih.gov/31296259","citation_count":47,"is_preprint":false},{"pmid":"23967156","id":"PMC_23967156","title":"Transcription factor TFAP2C regulates major programs required for murine fetal germ cell maintenance and haploinsufficiency predisposes to teratomas in male mice.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23967156","citation_count":41,"is_preprint":false},{"pmid":"32587258","id":"PMC_32587258","title":"TFAP2C facilitates somatic cell reprogramming by inhibiting c-Myc-dependent apoptosis and promoting mesenchymal-to-epithelial transition.","date":"2020","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/32587258","citation_count":36,"is_preprint":false},{"pmid":"38243114","id":"PMC_38243114","title":"Lineage regulators TFAP2C and NR5A2 function as bipotency activators in totipotent embryos.","date":"2024","source":"Nature structural & molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/38243114","citation_count":35,"is_preprint":false},{"pmid":"19458056","id":"PMC_19458056","title":"Interaction of TFAP2C with the estrogen receptor-alpha promoter is controlled by chromatin structure.","date":"2009","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/19458056","citation_count":34,"is_preprint":false},{"pmid":"26832794","id":"PMC_26832794","title":"EGFR Is Regulated by TFAP2C in Luminal Breast Cancer and Is a Target for Vandetanib.","date":"2016","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/26832794","citation_count":33,"is_preprint":false},{"pmid":"32563982","id":"PMC_32563982","title":"TFAP2C-mediated LINC00922 signaling underpins doxorubicin-resistant osteosarcoma.","date":"2020","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/32563982","citation_count":32,"is_preprint":false},{"pmid":"26811378","id":"PMC_26811378","title":"Tpbpa-Cre-mediated deletion of TFAP2C leads to deregulation of Cdkn1a, Akt1 and the ERK pathway, causing placental growth arrest.","date":"2016","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/26811378","citation_count":31,"is_preprint":false},{"pmid":"31636386","id":"PMC_31636386","title":"TFAP2C regulates carbonic anhydrase XII in human breast cancer.","date":"2019","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/31636386","citation_count":26,"is_preprint":false},{"pmid":"36936807","id":"PMC_36936807","title":"Fibroblast exosomal TFAP2C induced by chitosan oligosaccharides promotes peripheral axon regeneration via the miR-132-5p/CAMKK1 axis.","date":"2023","source":"Bioactive materials","url":"https://pubmed.ncbi.nlm.nih.gov/36936807","citation_count":26,"is_preprint":false},{"pmid":"22878616","id":"PMC_22878616","title":"Expression of the RET proto-oncogene is regulated by TFAP2C in breast cancer independent of the estrogen receptor.","date":"2012","source":"Annals of surgical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/22878616","citation_count":24,"is_preprint":false},{"pmid":"26063869","id":"PMC_26063869","title":"Reduced Gene Dosage of Tfap2c Impairs Trophoblast Lineage Differentiation and Alters Maternal Blood Spaces in the Mouse Placenta.","date":"2015","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/26063869","citation_count":22,"is_preprint":false},{"pmid":"21564135","id":"PMC_21564135","title":"The role of BLIMP1 and its putative downstream target TFAP2C in germ cell development and germ cell tumours.","date":"2011","source":"International journal of andrology","url":"https://pubmed.ncbi.nlm.nih.gov/21564135","citation_count":21,"is_preprint":false},{"pmid":"36230734","id":"PMC_36230734","title":"TFAP2C Knockdown Sensitizes Bladder Cancer Cells to Cisplatin Treatment via Regulation of EGFR and NF-κB.","date":"2022","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/36230734","citation_count":20,"is_preprint":false},{"pmid":"24023917","id":"PMC_24023917","title":"Human Melanoma cells over-express extracellular matrix 1 (ECM1) which is regulated by TFAP2C.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24023917","citation_count":20,"is_preprint":false},{"pmid":"16794002","id":"PMC_16794002","title":"Proteomic identification of AP2 gamma as a rat placental lactogen II trophoblast cell-specific enhancer binding protein.","date":"2006","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/16794002","citation_count":18,"is_preprint":false},{"pmid":"31619506","id":"PMC_31619506","title":"A TFAP2C Gene Signature Is Predictive of Outcome in HER2-Positive Breast Cancer.","date":"2019","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/31619506","citation_count":17,"is_preprint":false},{"pmid":"38789684","id":"PMC_38789684","title":"Tead4 and Tfap2c generate bipotency and a bistable switch in totipotent embryos to promote robust lineage diversification.","date":"2024","source":"Nature structural & molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/38789684","citation_count":16,"is_preprint":false},{"pmid":"34976158","id":"PMC_34976158","title":"Anlotinib inhibits the proliferation, migration and invasion, and induces apoptosis of breast cancer cells by downregulating TFAP2C.","date":"2021","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/34976158","citation_count":15,"is_preprint":false},{"pmid":"38574734","id":"PMC_38574734","title":"Defining a TFAP2C-centered transcription factor network during murine peri-implantation.","date":"2024","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/38574734","citation_count":14,"is_preprint":false},{"pmid":"38243003","id":"PMC_38243003","title":"TFAP2C Activates CST1 Transcription to Facilitate Breast Cancer Progression and Suppress Ferroptosis.","date":"2024","source":"Biochemical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/38243003","citation_count":12,"is_preprint":false},{"pmid":"35524544","id":"PMC_35524544","title":"Oncogenic LINC00857 recruits TFAP2C to elevate FAT1 expression in gastric cancer.","date":"2022","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/35524544","citation_count":10,"is_preprint":false},{"pmid":"36752341","id":"PMC_36752341","title":"KLF14/miR-1283/TFAP2C axis inhibits HER2-positive breast cancer progression via declining tumor cell proliferation.","date":"2023","source":"Molecular carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/36752341","citation_count":10,"is_preprint":false},{"pmid":"33718178","id":"PMC_33718178","title":"Fragile Gene WWOX Guides TFAP2A/TFAP2C-Dependent Actions Against Tumor Progression in Grade II Bladder Cancer.","date":"2021","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/33718178","citation_count":10,"is_preprint":false},{"pmid":"20131354","id":"PMC_20131354","title":"Loss of transcription factor AP-2gamma/TFAP2C impairs branching morphogenesis of the murine mammary gland.","date":"2010","source":"Developmental dynamics : an official publication of the American Association of Anatomists","url":"https://pubmed.ncbi.nlm.nih.gov/20131354","citation_count":10,"is_preprint":false},{"pmid":"32423796","id":"PMC_32423796","title":"MiR-29b-3p cooperates with miR-29c-3p to affect the malignant biological behaviors in T-cell acute lymphoblastic leukemia via TFAP2C/GPX1 axis.","date":"2020","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/32423796","citation_count":9,"is_preprint":false},{"pmid":"37191968","id":"PMC_37191968","title":"TFAP2C inhibits cell autophagy to alleviate myocardial ischemia/reperfusion injury by regulating miR-23a-5p/SFRP5/Wnt5a axis.","date":"2023","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/37191968","citation_count":8,"is_preprint":false},{"pmid":"32240977","id":"PMC_32240977","title":"CRISPR-on for activation of endogenous SMARCA4 and TFAP2C expression in bovine embryos.","date":"2020","source":"Reproduction (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/32240977","citation_count":8,"is_preprint":false},{"pmid":"39536858","id":"PMC_39536858","title":"TFAP2C/FLT3 axis reduces ferroptosis in breast cancer cells by inhibiting mitochondrial autophagy.","date":"2024","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/39536858","citation_count":8,"is_preprint":false},{"pmid":"23764310","id":"PMC_23764310","title":"High TFAP2C/low CD44 expression is associated with an increased rate of pathologic complete response following neoadjuvant chemotherapy in breast cancer.","date":"2013","source":"The Journal of surgical research","url":"https://pubmed.ncbi.nlm.nih.gov/23764310","citation_count":8,"is_preprint":false},{"pmid":"37169570","id":"PMC_37169570","title":"TFAP2C exacerbates psoriasis-like inflammation by promoting Th17 and Th1 cells activation through regulating TEAD4 transcription.","date":"2023","source":"Allergologia et immunopathologia","url":"https://pubmed.ncbi.nlm.nih.gov/37169570","citation_count":7,"is_preprint":false},{"pmid":"33128099","id":"PMC_33128099","title":"LncRNA RP11-84E24.3 drives tumorigenesis and epithelial-to-mesenchymal transition of glioma cells by promoting TFAP2C-mediated activation of SNAI1.","date":"2020","source":"Journal of neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/33128099","citation_count":7,"is_preprint":false},{"pmid":"40664662","id":"PMC_40664662","title":"Combining decitabine with radiotherapy to enhance nasopharyngeal carcinoma radiosensitivity via the TFAP2C-OTUD1-SLC25A11 axis.","date":"2025","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/40664662","citation_count":4,"is_preprint":false},{"pmid":"33907498","id":"PMC_33907498","title":"Arid4b physically interacts with Tfap2c in mouse embryonic stem cells.","date":"2021","source":"Turkish journal of biology = Turk biyoloji dergisi","url":"https://pubmed.ncbi.nlm.nih.gov/33907498","citation_count":4,"is_preprint":false},{"pmid":"38654453","id":"PMC_38654453","title":"LncRNA PART1 Attenuates Myocardial Ischemia-Reperfusion Injury by Regulating TFAP2C/DUSP5 Axis via miR-302a-3p.","date":"2024","source":"Korean circulation journal","url":"https://pubmed.ncbi.nlm.nih.gov/38654453","citation_count":4,"is_preprint":false},{"pmid":"34513711","id":"PMC_34513711","title":"Corrigendum: Fragile Gene WWOX Guides TFAP2A/TFAP2C-Dependent Actions Against Tumor Progression in Grade II Bladder Cancer.","date":"2021","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34513711","citation_count":4,"is_preprint":false},{"pmid":"39625795","id":"PMC_39625795","title":"TFAP2C is a key regulator of intrauterine trophoblast cell invasion and deep hemochorial placentation.","date":"2024","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/39625795","citation_count":3,"is_preprint":false},{"pmid":"40837414","id":"PMC_40837414","title":"Menin facilitates the cell proliferation of bladder cancer via modulating the TFAP2C/β-catenin axis.","date":"2025","source":"Genes & diseases","url":"https://pubmed.ncbi.nlm.nih.gov/40837414","citation_count":3,"is_preprint":false},{"pmid":"35170139","id":"PMC_35170139","title":"Generation of Tfap2c-T2A-tdTomato knock-in reporter rats via adeno-associated virus-mediated efficient gene targeting.","date":"2022","source":"Molecular reproduction and development","url":"https://pubmed.ncbi.nlm.nih.gov/35170139","citation_count":3,"is_preprint":false},{"pmid":"38165360","id":"PMC_38165360","title":"Does TFAP2C govern conflicting cell fates in mouse preimplantation embryos?","date":"2024","source":"Reproduction (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/38165360","citation_count":3,"is_preprint":false},{"pmid":"39603379","id":"PMC_39603379","title":"TFAP2C-DDR1 axis regulates resistance to CDK4/6 inhibitor in breast cancer.","date":"2024","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/39603379","citation_count":2,"is_preprint":false},{"pmid":"39716275","id":"PMC_39716275","title":"TFAP2C-mediated transcriptional activation of STEAP3 promotes lung squamous cell carcinoma progression by regulating the β-catenin pathway.","date":"2024","source":"Biology direct","url":"https://pubmed.ncbi.nlm.nih.gov/39716275","citation_count":2,"is_preprint":false},{"pmid":"40541807","id":"PMC_40541807","title":"TFAP2C drives cisplatin resistance in bladder cancer by upregulating YAP and activating β-catenin signaling.","date":"2025","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/40541807","citation_count":1,"is_preprint":false},{"pmid":"39554130","id":"PMC_39554130","title":"TFAP2C is a key regulator of intrauterine trophoblast cell invasion and deep hemochorial placentation.","date":"2024","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/39554130","citation_count":1,"is_preprint":false},{"pmid":"38253280","id":"PMC_38253280","title":"Transcriptional mechanism of E2F1/TFAP2C/NRF1 in regulating KANK2 gene in nephrotic syndrome.","date":"2024","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/38253280","citation_count":1,"is_preprint":false},{"pmid":"41524974","id":"PMC_41524974","title":"Propofol attenuates angiogenesis by activating endoplasmic reticulum stress to suppress TFAP2C-driven VEGFA transcription.","date":"2026","source":"Apoptosis : an international journal on programmed cell death","url":"https://pubmed.ncbi.nlm.nih.gov/41524974","citation_count":1,"is_preprint":false},{"pmid":"40667743","id":"PMC_40667743","title":"TFAP2C Affects PI3K/AKT/mTOR Pathway-Mediated EMT for Glioblastoma Development Through Transcriptional Regulation.","date":"2025","source":"Cell biology international","url":"https://pubmed.ncbi.nlm.nih.gov/40667743","citation_count":0,"is_preprint":false},{"pmid":"41703284","id":"PMC_41703284","title":"TFAP2C protects against ferroptosis in ovarian cancer through the KEAP1-NRF2 axis by recruiting HDAC1/2.","date":"2026","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/41703284","citation_count":0,"is_preprint":false},{"pmid":"40600821","id":"PMC_40600821","title":"Deciphering the role of cis-regulatory elements and TFAP2C in the activation of zygotic Sox2 expression in mouse preimplantation embryos.","date":"2025","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/40600821","citation_count":0,"is_preprint":false},{"pmid":"38645262","id":"PMC_38645262","title":"Regulation of Enhancers by SUMOylation Through TFAP2C Binding and Recruitment of HDAC Complex to the Chromatin.","date":"2024","source":"Research square","url":"https://pubmed.ncbi.nlm.nih.gov/38645262","citation_count":0,"is_preprint":false},{"pmid":"40777819","id":"PMC_40777819","title":"TFAP2C activates PTGES through the NOTCH3 signaling pathway to affect gefitinib resistance in lung adenocarcinoma.","date":"2025","source":"Journal of clinical biochemistry and nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/40777819","citation_count":0,"is_preprint":false},{"pmid":"41700779","id":"PMC_41700779","title":"Simultaneous CRISPR-on activation of TFAP2C and SMARCA4 promotes development of trophoblast-fate cells in bovine embryos†.","date":"2026","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/41700779","citation_count":0,"is_preprint":false},{"pmid":"41035077","id":"PMC_41035077","title":"Single-cell transcriptomics of organoids reveals transcriptional control of germline stem cell fate by an E2F1-TFAP2C-SOX17 positive-feedback loop in Turner syndrome.","date":"2025","source":"Cell & bioscience","url":"https://pubmed.ncbi.nlm.nih.gov/41035077","citation_count":0,"is_preprint":false},{"pmid":"42008486","id":"PMC_42008486","title":"Prion propagation is controlled by a hierarchical network involving the nuclear Tfap2c and hnRNP K factors and the cytosolic mTORC1 complex.","date":"2026","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/42008486","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.05.01.25326828","title":"NF-κB-Mediated Disruption of Key Transcription Factors Predisposes Lower Esophageal Squamous Epithelium to Esophageal Adenocarcinoma: a systematic review","date":"2025-05-02","source":"bioRxiv","url":"https://doi.org/10.1101/2025.05.01.25326828","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.06.04.657951","title":"Molecular profiling of bovine primordial germ cell specification and migration onset reveals a conserved program in bilaminar disc embryos","date":"2025-06-08","source":"bioRxiv","url":"https://doi.org/10.1101/2025.06.04.657951","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.06.28.662155","title":"Prenatal cannabis smoke exposure alters placental development in a murine model of pregnancy","date":"2025-07-05","source":"bioRxiv","url":"https://doi.org/10.1101/2025.06.28.662155","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.11.11.623003","title":"The transcription factor GABPA is a master regulator of naïve pluripotency","date":"2024-11-12","source":"bioRxiv","url":"https://doi.org/10.1101/2024.11.11.623003","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.07.12.603294","title":"METTL3 shapes m6A epitranscriptomic landscape for successful human placentation","date":"2024-07-13","source":"bioRxiv","url":"https://doi.org/10.1101/2024.07.12.603294","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.06.27.600209","title":"Inter-cellular mRNA Transfer Alters Human Pluripotent Stem Cell State","date":"2024-06-27","source":"bioRxiv","url":"https://doi.org/10.1101/2024.06.27.600209","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":43907,"output_tokens":11319,"usd":0.150753,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":22299,"output_tokens":5468,"usd":0.124097,"stage2_stop_reason":"end_turn"},"total_usd":0.27485,"stage1_batch_id":"msgbatch_017qqVz33Ga63SCDwzb35XPb","stage2_batch_id":"msgbatch_01Scr2Ei9x4HJMiRGxwrmvLK","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2007,\n      \"finding\": \"TFAP2C directly binds the ERα (ESR1) promoter to activate transcription and regulates multiple estrogen signaling pathways (ERα, GPR30, FoxM1) in breast cancer cells; knockdown of TFAP2C abrogates mitogenic response to estrogen and reduces hormone-responsive tumor growth in xenografts.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP), gene knockdown (siRNA), xenograft assays, expression analysis\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP confirming direct promoter binding, siRNA knockdown with defined cellular and in vivo phenotypes, multiple orthogonal methods in a single focused study\",\n      \"pmids\": [\"17875680\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"TFAP2C binding to the ERα promoter is blocked by CpG methylation and histone deacetylation; treatment with 5-aza-dC and trichostatin A restores chromatin accessibility, enabling TFAP2C and RNA Pol II binding and ERα re-expression in ERα-negative breast cancer cells.\",\n      \"method\": \"ChIP, DNA methylation analysis, chromatin accessibility assay, drug treatment (AZA/TSA)\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP showing context-dependent promoter binding, chromatin accessibility assays, and pharmacologic rescue experiments in a single focused study\",\n      \"pmids\": [\"19458056\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Genome-wide ChIP-seq for TFAP2C in MCF-7 cells defined the consensus chromatin-binding sequence as SCCTSRGGS and identified 447 primary target genes including ESR1, FOXA1, GREB1, WWOX, MYC, RET, and members of the retinoic acid response pathway.\",\n      \"method\": \"ChIP-seq, expression microarray with TFAP2C knockdown\",\n      \"journal\": \"Genes, chromosomes & cancer\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genome-wide ChIP-seq combined with expression arrays after knockdown, rigorous identification of direct targets in a focused study\",\n      \"pmids\": [\"20629094\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"TFAP2C forms a ternary complex with Myc and the H3K4me3 demethylase KDM5B at the CDKN1A (p21cip) proximal promoter; all three proteins collaborate to repress p21, requiring the AP-2 binding site at -111/-103 and KDM5B demethylase activity. The TFAP2C C-terminal 270 aa are required for Myc and KDM5B interaction. Overexpression forces S-phase entry and attenuates checkpoint activation.\",\n      \"method\": \"Co-immunoprecipitation, ChIP, luciferase reporter assay, siRNA knockdown, domain-mapping mutagenesis\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal co-IP, ChIP at endogenous locus, domain mutagenesis, functional cell cycle readouts; multiple orthogonal methods\",\n      \"pmids\": [\"22371483\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"TFAP2C directly regulates GPX1 expression by binding to an AP-2 regulatory region in the GPX1 promoter; CpG methylation of this region in certain breast cancer cell lines blocks TFAP2C binding and silences GPX1, which can be reversed by 5-aza-dC treatment.\",\n      \"method\": \"ChIP-seq, siRNA knockdown, luciferase reporter assay, methylation analysis, 5-aza-dC treatment\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP-seq confirming direct binding, siRNA knockdown, epigenetic rescue experiments with multiple orthogonal methods\",\n      \"pmids\": [\"22964634\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"TFAP2C directly regulates expression of the RET proto-oncogene through five AP-2 binding sites in the RET promoter (confirmed by ChIP-seq and gel-shift), independently of estrogen receptor expression.\",\n      \"method\": \"ChIP-seq, gel-shift (EMSA), siRNA knockdown, luciferase reporter assay\",\n      \"journal\": \"Annals of surgical oncology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP-seq and EMSA confirming direct binding at multiple sites, ER-independent knockdown validation\",\n      \"pmids\": [\"22878616\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"TFAP2C directly binds an AP-2 regulatory region in the ECM1 promoter (confirmed by ChIP-seq and EMSA) and regulates ECM1 expression in melanoma cells; knockdown or overexpression of TFAP2C correspondingly decreases or increases ECM1.\",\n      \"method\": \"ChIP-seq, EMSA (gel-shift), siRNA knockdown, adenoviral overexpression, luciferase reporter assay, 5' RACE\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-seq and EMSA confirming direct binding, knockdown and OE validation, single lab\",\n      \"pmids\": [\"24023917\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"TFAP2C is required for murine fetal primordial germ cell (PGC) maintenance and directly binds regulatory regions of target genes including Sfrp1, Dmrt1, Nanos3, c-Kit, Cdk6, Cdkn1a, Fgf4, Klf4, Dnmt3b, and Dnmt3l (confirmed by ChIP); haploinsufficiency predisposes to teratomas on 129S2/Sv background.\",\n      \"method\": \"Global gene expression profiling (knockout mESCs and PGC-like cells), chromatin immunoprecipitation (ChIP), conditional knockout mouse model\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic loss-of-function with specific in vivo phenotype, ChIP confirming direct binding at multiple target loci, multiple orthogonal methods\",\n      \"pmids\": [\"23967156\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Knockdown of TFAP2C in luminal breast carcinoma cells induces epithelial-mesenchymal transition (loss of luminal gene expression, gain of basal gene expression). Conditional knockout of Tcfap2c in mouse mammary epithelium (MMTV-Cre) reduces CD24hi/CD49fmid luminal cell population and increases CD24mid/CD49fhi basal cell population.\",\n      \"method\": \"siRNA knockdown, conditional knockout mouse model, FACS analysis of mammary cell populations, expression profiling\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — loss-of-function in both human cell lines and conditional knockout mouse model with defined cellular phenotype, multiple orthogonal readouts\",\n      \"pmids\": [\"24469049\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"TFAP2C promotes NSCLC cell cycle progression and tumorigenesis by transcriptionally inducing oncogenic miR-183 (which blocks AKAP12-mediated cyclin D1 inhibition) and simultaneously downregulating tumor-suppressive miR-33a (resulting in CDK6 activation); validated in xenograft mouse model.\",\n      \"method\": \"Overexpression/knockdown assays, microRNA expression analysis, xenograft mouse model, cell cycle analysis\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — defined pathway via miRNA intermediaries, xenograft validation, single lab with multiple methods\",\n      \"pmids\": [\"27593936\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"TFAP2C transcriptionally upregulates TGFBR1 in NSCLC cells, which activates PAK1 signaling to promote tumor cell proliferation, migration, and EMT; validated in xenograft model.\",\n      \"method\": \"Microarray analysis, overexpression/knockdown assays, xenograft model, expression analysis of patient tissue\",\n      \"journal\": \"Experimental & molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — pathway defined by expression and knockdown, lacks direct promoter binding confirmation (ChIP), xenograft validation provides in vivo support\",\n      \"pmids\": [\"27885255\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"TFAP2C directly regulates EGFR expression in luminal breast cancer (ChIP-seq); co-knockdown of EGFR and TFAP2C target RET reduces proliferation more than either alone; vandetanib response depends on TFAP2C expression.\",\n      \"method\": \"ChIP-seq, siRNA knockdown, cell proliferation assays, xenograft assays\",\n      \"journal\": \"Molecular cancer therapeutics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP-seq confirming direct binding, genetic epistasis via dual knockdown, in vivo xenograft validation\",\n      \"pmids\": [\"26832794\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"TFAP2C regulates trophoblast proliferation and placental development by repressing Cdkn1a (p21) and Dusp6 to maintain ERK1/2 and AKT activation; loss of TFAP2C in TPBPA+ progenitors causes junctional zone growth arrest and reduced glycogen synthesis.\",\n      \"method\": \"Conditional knockout (Cre-lox), Western blot analysis of signaling pathways, gene expression analysis, knockdown in human trophoblast cell line (JAr)\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional knockout with specific cellular and signaling phenotype, validated in human cell line knockdown, multiple orthogonal methods\",\n      \"pmids\": [\"26811378\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"TFAP2C is upregulated during primed-to-naive pluripotency reversion, binds naive-specific enhancers genome-wide, facilitates opening of enhancers proximal to pluripotency factors (including a naive-specific OCT4/POU5F1 enhancer), and is required to maintain naive pluripotency and repress neuroectodermal differentiation.\",\n      \"method\": \"ATAC-seq, ChIP-seq, loss-of-function (siRNA/shRNA), gain-of-function in human ESCs, reporter assays\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genome-wide chromatin accessibility and binding mapping (ATAC-seq + ChIP-seq) combined with functional loss/gain experiments, multiple orthogonal methods\",\n      \"pmids\": [\"29695788\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"TFAP2C-bound naive enhancer at the OCT4 (POU5F1) locus is required for OCT4 expression and hPGCLC identity; CRISPR/Cas9 deletion of this enhancer impairs OCT4 expression and hPGCLC specification.\",\n      \"method\": \"ATAC-seq, CRISPR/Cas9 enhancer deletion, expression analysis in hPGCs and hPGCLCs\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — CRISPR deletion of specific enhancer with defined functional consequence, ATAC-seq chromatin mapping; single lab but rigorous\",\n      \"pmids\": [\"30590035\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"TFAP2C promotes colorectal cancer stemness and chemoresistance to 5-FU by inhibiting Hippo signaling via transcriptional upregulation of ROCK1 and ROCK2.\",\n      \"method\": \"Western blot, luciferase reporter assay, ChIP, in vitro and in vivo functional assays\",\n      \"journal\": \"Journal of experimental & clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and luciferase confirming direct transcriptional regulation, in vivo xenograft validation, single lab\",\n      \"pmids\": [\"29439714\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"TFAP2C acts as the first transcription factor in a two-stage chromatin-remodeling cascade during epidermal differentiation: TFAP2C initiates surface ectoderm chromatin landscape and induces p63 expression and binding sites, enabling p63 to then autoregulate and mature the keratinocyte program. TFAP2C alone (not p63) is sufficient to initiate surface ectoderm differentiation.\",\n      \"method\": \"ATAC-seq, ChIP-seq, RNA-seq, overexpression of TFAP2C in human PSCs, inference regulatory network analysis, functional keratinocyte differentiation assays\",\n      \"journal\": \"Cell stem cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genome-wide chromatin and binding analyses combined with gain-of-function experiments showing sufficiency, epistasis between TFAP2C and p63\",\n      \"pmids\": [\"30686763\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"TFAP2C regulates cell collision guidance (reorientation of fibroblasts upon collision) in part by controlling expression of RND3; RND3 localizes to cell-cell collision zones and downregulates actomyosin activity there, enabling anisotropic extracellular matrix generation. Loss of TFAP2C leads to failure of cell collision guidance and isotropic matrix.\",\n      \"method\": \"Transcription factor knockdown/overexpression, live cell imaging, Vicsek modeling, RND3 localization experiments, actomyosin activity assays\",\n      \"journal\": \"Nature materials\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — combined experimentation and mathematical modeling, RND3 localization, actomyosin functional readout, multiple orthogonal methods\",\n      \"pmids\": [\"31659294\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"TFAP2C directly regulates CA12 (carbonic anhydrase XII) expression in luminal breast cancer by binding its promoter region (ChIP-seq), and also indirectly through upregulation of ERα; CA12 is epigenetically silenced in basal breast cancer by histone deacetylation and CpG methylation.\",\n      \"method\": \"ChIP-seq, siRNA knockdown, methylation analysis, TSA/5-aza-dC treatment, expression analysis in primary tumors\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-seq confirming direct binding, epigenetic rescue experiments, single lab\",\n      \"pmids\": [\"31636386\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"TFAP2C increases NSCLC cell proliferation by downregulating GADD45B and PMAIP1 at both mRNA and protein levels, promoting cell cycle progression and motility.\",\n      \"method\": \"Microarray analysis, overexpression/knockdown, cell proliferation and motility assays\",\n      \"journal\": \"Biological research\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, expression-based validation without direct promoter binding confirmation\",\n      \"pmids\": [\"31296259\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"TFAP2C promotes mesenchymal-to-epithelial transition (MET) during somatic cell reprogramming by directly binding epithelial gene promoters (ChIP-qPCR) to activate their expression; knockdown of E-cadherin (Cdh1), a direct TFAP2C target, antagonizes TFAP2C-mediated reprogramming. TFAP2C also inhibits c-Myc-dependent apoptosis during reprogramming.\",\n      \"method\": \"RNA-seq, ChIP-qPCR, overexpression/knockdown during iPSC reprogramming, siRNA knockdown of downstream targets\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-qPCR confirming direct binding to epithelial gene promoters, genetic epistasis via Cdh1 knockdown, single lab\",\n      \"pmids\": [\"32587258\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"METTL3 m6A-methylates TFAP2C mRNA, and this modification is read by IGF2BP1; this enhances TFAP2C mRNA stability and promotes seminoma cell survival under cisplatin treatment by upregulating DNA repair-related genes.\",\n      \"method\": \"m6A sequencing, RNA immunoprecipitation (RIP), expression analysis, knockdown/overexpression\",\n      \"journal\": \"Journal of cellular and molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — RIP confirming m6A reader binding, mRNA stability assays, mechanistic pathway placed in context, single lab\",\n      \"pmids\": [\"32857912\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"TFAP2C suppresses miR-23a-5p expression by directly binding the miR-23a promoter (ChIP assay); miR-23a-5p targets SFRP5, an inhibitor of Wnt5a; through this axis, TFAP2C inhibits autophagy to reduce cardiomyocyte H/R injury.\",\n      \"method\": \"ChIP assay, dual-luciferase reporter assay, RIP assay, overexpression/knockdown, cell viability assays\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP confirming direct promoter binding for miR-23a, multiple assays, single lab\",\n      \"pmids\": [\"37191968\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"GATA3 or GATA2 combined with SOX17 and TFAP2C are sufficient to generate human PGCLCs from pluripotent cells; SOX17, TFAP2C, and BLIMP1 alone are insufficient. GATA3/GATA2 knockouts dose-dependently impair BMP-induced hPGCLC specification, while GATA3/GATA2 expression is unaffected by SOX17, TFAP2C, or BLIMP1 knockouts—placing GATA3/GATA2 upstream of or parallel to SOX17/TFAP2C in BMP signaling.\",\n      \"method\": \"Transcription factor overexpression in human PSCs, gene knockout (siRNA/shRNA), hPGCLC induction assays, xenogeneic ovary reconstitution\",\n      \"journal\": \"Life science alliance\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis combined with sufficiency experiments (TF-induced hPGCLCs) and functional in vivo reconstitution; multiple orthogonal methods\",\n      \"pmids\": [\"33608411\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TFAP2C physically interacts with Arid4b (a Sin3a corepressor complex member) in mouse ESCs, identified by endogenous co-immunoprecipitation and proximity ligation assay; this interaction is linked to repression of a subset of Tfap2c-regulated genes during meso/endoderm differentiation.\",\n      \"method\": \"Co-immunoprecipitation (endogenous), proximity ligation assay (PLA), ChIP (H3K27Ac), differentiation assays\",\n      \"journal\": \"Turkish journal of biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — endogenous co-IP confirmed by PLA, but functional link to repression inferred; single lab, single paper\",\n      \"pmids\": [\"33907498\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"TFAP2C transcriptionally activates PCAT1 lncRNA expression in prostate cancer cells; PCAT1 then inhibits ferroptosis through c-Myc/miR-25-3p/SLC7A11 signaling to promote docetaxel resistance.\",\n      \"method\": \"ChIP assay, luciferase reporter assay, RNA sequencing, overexpression/knockdown, ferroptosis assays\",\n      \"journal\": \"Frontiers in oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and luciferase confirming direct transcriptional activation of PCAT1, functional ferroptosis readouts, single lab\",\n      \"pmids\": [\"35402284\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TFAP2C targets the pri-miRNA-132 gene in dorsal root ganglion neurons and represses miR-132-5p expression; exosomal TFAP2C (from fibroblasts) is transferred into axons where it promotes axon regeneration via the miR-132-5p/CAMKK1 axis.\",\n      \"method\": \"ChIP assay (TFAP2C binding to pri-miRNA-132), exosome isolation and proteomic identification, miRNA expression analysis, axon regeneration assays in vitro and in vivo (rat sciatic nerve model)\",\n      \"journal\": \"Bioactive materials\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP confirming direct binding to miRNA gene, functional in vivo nerve regeneration readout, single lab\",\n      \"pmids\": [\"36936807\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"In totipotent mouse embryos, TFAP2C acts as a 'bipotency activator' by binding and activating both early TE and ICM lineage genes at the 2–8-cell stages; upon trophoblast commitment, TFAP2C leaves ICM gene loci and co-occupies late TE genes with CDX2, then extra-embryonic ectoderm genes with SOX2. Tfap2c deficiency downregulates both early ICM genes (Nanog, Nr5a2, Tdgf1) and early TE genes (Tfeb, Itgb5), and increases ICM apoptosis.\",\n      \"method\": \"uliCUT&RUN-seq (in vivo TF binding), embryo Tfap2c knockout, expression analysis at multiple developmental stages\",\n      \"journal\": \"Nature structural & molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genome-wide TF binding in vivo using uliCUT&RUN-seq combined with loss-of-function in embryos and multi-stage developmental readouts; replicated across two Nature Struct Mol Biol papers (38243114, 38789684)\",\n      \"pmids\": [\"38243114\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"TFAP2C and TEAD4 together accelerate loss of totipotency and promote lineage diversification by establishing a bistable switch; they paradoxically activate both TE specifiers and ICM specifiers in bipotent cells, with asymmetric apical domain segregation resolving this into Hippo-OFF (TE) or Hippo-ON (ICM) fates. TFAP2C activates specifiers of both ICM and TE fate.\",\n      \"method\": \"Overexpression and loss-of-function of TFAP2C and TEAD4 in mouse embryos, Hippo signaling readouts, live imaging of apical domain, lineage marker analysis\",\n      \"journal\": \"Nature structural & molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic gain/loss-of-function in embryos with mechanistic Hippo signaling readouts, consistent with independent data from PMID 38243114\",\n      \"pmids\": [\"38789684\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"TFAP2C binds to the Sox2 proximal promoter in mouse preimplantation embryos to activate Sox2 transcription; TFAP2C and Hippo signaling cooperatively regulate Sox2 expression.\",\n      \"method\": \"ChIP/CUT&RUN in embryos, loss-of-function via TFAP2C knockdown/knockout, cis-regulatory element deletion, Sox2 expression analysis\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct binding to Sox2 promoter confirmed, functional cooperation with Hippo pathway demonstrated, single lab\",\n      \"pmids\": [\"40600821\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"TFAP2C defines a regulatory network in murine peri-implantation embryos involving TEAD4 and KLF5; maternal retinoic acid metabolism regulates TFAP2C expression and function via active demethylation of SINEs (RARG-TFAP2C-TEAD4/KLF5 axis); both genomic imprinting and SNPs influence TF positioning through TFAP2C.\",\n      \"method\": \"uliCUT&RUN-seq (genome-wide TF binding), TFAP2C loss-of-function, retinoic acid pathway manipulation, promoter-enhancer interaction analysis\",\n      \"journal\": \"Developmental cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genome-wide binding combined with genetic and metabolic perturbations, single lab\",\n      \"pmids\": [\"38574734\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"TFAP2C transcriptionally activates CST1 (cystatin SN) expression by binding its promoter (dual-luciferase and ChIP assay); TFAP2C/CST1 axis promotes breast cancer cell proliferation and suppresses ferroptosis (GPX4-dependent).\",\n      \"method\": \"Dual-luciferase reporter assay, ChIP, siRNA knockdown, overexpression, cell cycle/apoptosis/ferroptosis assays, xenograft model\",\n      \"journal\": \"Biochemical genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and luciferase confirming direct promoter binding, functional ferroptosis and proliferation readouts, in vivo validation, single lab\",\n      \"pmids\": [\"38243003\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"TFAP2C transcriptionally activates DDR1 in palbociclib-resistant breast cancer cells; inhibition of TFAP2C re-sensitizes resistant cells to palbociclib. TFAP2C-DDR1 gene signatures are enriched in patients after palbociclib treatment.\",\n      \"method\": \"Quantitative high-throughput combination screening, genomics/proteomics, siRNA knockdown, xenograft model, GSEA of clinical data\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — transcriptional regulation inferred from expression and knockdown without direct ChIP confirmation cited in abstract; xenograft validation provides in vivo support; single lab\",\n      \"pmids\": [\"39603379\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"TFAP2C transcriptionally activates FLT3 expression (confirmed by dual-luciferase and ChIP); the TFAP2C/FLT3 axis inhibits ferroptosis in breast cancer by suppressing mitochondrial autophagy.\",\n      \"method\": \"Dual-luciferase reporter assay, ChIP, knockdown/overexpression, autophagy and ferroptosis assays\",\n      \"journal\": \"The international journal of biochemistry & cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and luciferase confirming direct transcriptional activation, functional ferroptosis/autophagy readouts, single lab\",\n      \"pmids\": [\"39536858\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"TFAP2C directly binds the YAP promoter to activate its transcription (dual-luciferase and ChIP); TFAP2C promotes cisplatin resistance in bladder cancer through YAP upregulation and downstream β-catenin pathway activation.\",\n      \"method\": \"Dual-luciferase reporter assay, ChIP, siRNA knockdown, xenograft model\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and luciferase confirming direct promoter binding, in vivo xenograft validation, single lab\",\n      \"pmids\": [\"40541807\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Knockdown of UBA2 (SUMO activating enzyme) increases TFAP2C binding to enhancers genome-wide (not due to TFAP2C SUMOylation itself); TFAP2C recruits HDAC1 to chromatin, and TFAP2C knockdown reduces HDAC1 binding and increases H3K27Ac at enhancers, indicating TFAP2C is required for HDAC machinery recruitment to suppress enhancer activity.\",\n      \"method\": \"ChIP-seq (UBA2 KD and TFAP2C KD), proteomics of TFAP2C interactome on chromatin, molecular biology (ChIP for HDAC1), SUMOylation inhibitor\",\n      \"journal\": \"Research square (preprint)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-seq and proteomics of chromatin-bound TFAP2C interactome, multiple orthogonal methods, but preprint status warrants caution\",\n      \"pmids\": [\"38645262\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"TFAP2C is required for invasive trophoblast cell-specific functions in rat hemochorial placentation; conditional (Cre-lox) invasive trophoblast-specific disruption of Tfap2c inhibits intrauterine trophoblast invasion and causes intrauterine and postnatal growth restriction. Homozygous global disruption is prenatally lethal. Monoallelic conditional disruption does not impair invasion, indicating gene dosage dependence.\",\n      \"method\": \"CRISPR/Cas9 global genome editing, Cre-lox conditional mutagenesis, histological analysis of placentation site, growth measurements\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell type-specific conditional knockout with defined in vivo phenotype, dosage-sensitivity established by monoallelic vs biallelic comparison; confirmed in two publications (peer-reviewed and preprint: 39625795, 39554130)\",\n      \"pmids\": [\"39625795\", \"39554130\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"TFAP2C directly binds the STEAP3 promoter and positively regulates its expression (ChIP and luciferase); TFAP2C/STEAP3 axis activates β-catenin signaling to promote lung squamous cell carcinoma progression.\",\n      \"method\": \"ChIP assay, luciferase reporter assay, siRNA knockdown, overexpression, in vivo xenograft model\",\n      \"journal\": \"Biology direct\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and luciferase confirming direct promoter binding, in vivo validation, single lab\",\n      \"pmids\": [\"39716275\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"TFAP2C binds to the KEAP1 promoter and recruits HDAC1/2, leading to H3K27 deacetylation and transcriptional repression of KEAP1; reduced KEAP1 stabilizes NRF2 protein, activating NRF2-dependent antioxidant transcription and conferring ferroptosis resistance in ovarian cancer.\",\n      \"method\": \"ChIP assay, dual-luciferase reporter assay, knockdown/overexpression, ROS/Fe2+/lipid peroxidation assays, mitochondrial membrane potential assay, rescue experiments\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP confirming TFAP2C binding to KEAP1 promoter with HDAC1/2 recruitment, epigenetic mechanism defined, single lab\",\n      \"pmids\": [\"41703284\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"E2F1 activates TFAP2C transcription by binding to its promoter, and the resulting E2F1-TFAP2C-SOX17 positive-feedback loop controls human germline stem cell fate (hPGCLC identity) in organoids from Turner syndrome iPSCs; E2F1 knockout impairs hPGCLC specification.\",\n      \"method\": \"Single-cell transcriptomics, organoid differentiation system, ChIP (E2F1 binding to TFAP2C promoter), E2F1 knockout, expression analysis\",\n      \"journal\": \"Cell & bioscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP confirming direct E2F1 binding to TFAP2C promoter, genetic knockout, single lab\",\n      \"pmids\": [\"41035077\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"TFAP2C deletion is synthetic viable with HNRNPK depletion in glioma cells; HNRNPK depletion inhibits mTORC1 and increases prion propagation; TFAP2C overexpression enhances mTORC1 downstream functions. Co-deletion of TFAP2C with HNRNPK restores mTORC1 activity and reverses prion elevation, establishing epistatic interaction between TFAP2C, HNRNPK, and mTORC1 in metabolic and prion regulation.\",\n      \"method\": \"Synthetic-viability CRISPR screen, mTOR signaling assays, metabolic assays (ATP, autophagy), prion propagation assays, genetic epistasis\",\n      \"journal\": \"PLoS pathogens\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — CRISPR screen establishing genetic interaction, mTORC1 signaling readouts, prion functional assay; epistatic relationship defined, single lab\",\n      \"pmids\": [\"42008486\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"TFAP2C directly binds the TFAP2C promoter region and activates TFAP2C transcription in response to PART1/miR-302a-3p signaling; TFAP2C directly binds the DUSP5 promoter to activate DUSP5 expression, thereby suppressing autophagy and apoptosis in H/R-injured cardiomyocytes.\",\n      \"method\": \"Dual-luciferase reporter assay, ChIP assay, siRNA knockdown, flow cytometry, TUNEL, MIRI mouse model\",\n      \"journal\": \"Korean circulation journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and luciferase confirming direct binding to DUSP5 promoter, in vivo MIRI model validation, single lab\",\n      \"pmids\": [\"38654453\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"TFAP2C directly binds to the PI3K promoter and activates its transcription (confirmed by ChIP and luciferase); through this mechanism TFAP2C activates the PI3K/AKT/mTOR pathway to promote EMT and proliferation in glioblastoma.\",\n      \"method\": \"ChIP assay, dual-luciferase reporter assay, siRNA knockdown, co-overexpression rescue, xenograft model\",\n      \"journal\": \"Cell biology international\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and luciferase confirming direct promoter binding, in vivo xenograft validation, single lab\",\n      \"pmids\": [\"40667743\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"TFAP2C directly binds the VEGFA promoter to transcriptionally activate VEGFA expression in endothelial cells, facilitating VEGFA/VEGFR2-dependent angiogenesis; propofol suppresses this by activating ER stress (PERK/eIF2α phosphorylation) to reduce TFAP2C translation.\",\n      \"method\": \"ChIP assay, luciferase reporter assay, propofol treatment with ER stress pathway analysis, in vitro angiogenesis assays, in vivo angiogenesis model\",\n      \"journal\": \"Apoptosis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and luciferase confirming direct binding to VEGFA promoter, pharmacologic mechanism defined, single lab\",\n      \"pmids\": [\"41524974\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"In zebrafish, tfap2c (encoding AP-2 gamma) is expressed transiently in neural crest and non-neural ectoderm; simultaneous morpholino-knockdown of tfap2a and tfap2c completely prevents neural crest induction (epistasis showing redundancy), and reduces cranial placode derivatives. Single tfap2c knockdown alone shows no visible developmental defect.\",\n      \"method\": \"Antisense morpholino knockdown (single and double), transplant studies (cell autonomy), in situ hybridization, neural crest marker analysis in zebrafish embryos\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis through double knockdown demonstrating redundancy and cell-autonomous function, transplant experiments, focused developmental study\",\n      \"pmids\": [\"17258188\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"AP-2 gamma (TFAP2C ortholog) binds a specific enhancer element (FP2 DNase I-protected region) in the rat placental lactogen II (rPLII) gene 5' flanking region in trophoblast cells; this binding was confirmed by gel-shift assay with AP-2 gamma-specific antiserum and chromatin immunoprecipitation in Rcho giant cells; AP-2 gamma transactivates the enhancer in cotransfection assays.\",\n      \"method\": \"Protein purification by DNA affinity, HPLC-MALDI-TOF mass spectrometry identification, gel-shift assay (EMSA), ChIP, cotransfection luciferase assay\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro biochemical binding confirmed by EMSA, in vivo occupancy by ChIP, transactivation by luciferase; multiple orthogonal methods in single study\",\n      \"pmids\": [\"16794002\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"TFAP2C directly binds the TFAP2C (proximal) promoter region and activates PTGES transcription in lung adenocarcinoma cells (confirmed by ChIP and dual-luciferase); PTGES promotes gefitinib resistance through NOTCH3 signaling, and TFAP2C knockdown-mediated loss of PTGES is reversed by PTGES overexpression.\",\n      \"method\": \"ChIP assay, dual-luciferase reporter assay, GSEA, knockdown/overexpression in PC-9/GR cells, NOTCH3 inhibitor rescue\",\n      \"journal\": \"Journal of clinical biochemistry and nutrition\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and luciferase confirming direct binding to PTGES promoter, pathway defined through NOTCH3 inhibitor, single lab\",\n      \"pmids\": [\"40777819\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TFAP2C is a sequence-specific AP-2 family transcription factor that binds a SCCTSRGGS consensus element to directly activate or repress hundreds of target genes; it regulates pluripotency (maintaining naive human ESC state by opening enhancers near OCT4 and other factors), primordial germ cell specification and maintenance, trophoblast lineage commitment and invasive trophoblast function (essential for placentation), epidermal differentiation (by priming chromatin for subsequent p63 action), and luminal breast cancer identity (through direct regulation of ESR1/ERα, FOXA1, EGFR, RET, GPX1, CA12, and others); it represses CDKN1A (p21) via a ternary complex with Myc and the demethylase KDM5B; its activity at target promoters is gated by CpG methylation and histone deacetylation status; and it regulates cell collision guidance (via RND3/actomyosin) and axon regeneration (via miR-132-5p/CAMKK1), while interacting physically with the Sin3a complex member Arid4b and recruiting HDAC machinery to enhancers.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"TFAP2C is a sequence-specific AP-2 family transcription factor that recognizes the SCCTSRGGS consensus element and directly activates or represses several hundred target genes to control lineage specification, pluripotency, and proliferative programs [#2]. In early development it functions as a master regulator of cell-fate decisions: in totipotent mouse embryos it acts as a 'bipotency activator' that binds and activates both inner-cell-mass and trophectoderm genes, then resolves fate by partitioning between CDX2- and SOX2-bound loci, cooperating with TEAD4 and Hippo signaling to establish a bistable lineage switch [#27, #28, #29]. It is required for primordial germ cell maintenance and, together with SOX17 and GATA factors, is sufficient to drive human PGC-like cell specification, in part through a TFAP2C-bound enhancer at the OCT4/POU5F1 locus [#7, #14, #23]; it also maintains naive human pluripotency by opening enhancers near pluripotency genes [#13]. In differentiating tissues TFAP2C initiates the surface-ectoderm chromatin landscape and induces p63 to launch the keratinocyte program [#16], and it is essential for trophoblast proliferation and invasive trophoblast function during placentation, where loss causes growth restriction and lethality in a gene-dosage-dependent manner [#12, #36]. As a transcriptional regulator it both activates targets and recruits corepressor machinery: it forms a ternary complex with Myc and the demethylase KDM5B to repress CDKN1A (p21) and drive S-phase entry [#3], physically associates with the Sin3a-complex member Arid4b [#24], and recruits HDAC1/2 to enhancers and promoters to deacetylate H3K27 and suppress transcription [#35, #38]. In breast cancer it establishes and maintains luminal identity through direct regulation of ESR1/ERα, FOXA1, EGFR, RET, GPX1, and CA12, with binding at these targets gated by CpG methylation and histone deacetylation [#0, #1, #2, #4, #5, #11, #18]. Across diverse cancers TFAP2C activates oncogenic programs and confers therapy resistance, frequently by suppressing ferroptosis or activating PI3K/AKT, β-catenin, and NRF2 pathways through direct target activation [#31, #33, #34, #38, #42].\",\n  \"teleology\": [\n    {\n      \"year\": 2006,\n      \"claim\": \"Established that the AP-2 gamma factor binds and transactivates a defined enhancer in a trophoblast gene, providing the first direct biochemical evidence of its sequence-specific transcriptional activity.\",\n      \"evidence\": \"DNA-affinity purification, mass-spec identification, EMSA, ChIP and luciferase on the rat placental lactogen II enhancer in trophoblast cells\",\n      \"pmids\": [\"16794002\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Single target gene; genome-wide binding repertoire undefined\", \"Mammalian developmental requirement not yet tested\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Demonstrated through genetic epistasis that tfap2c functions redundantly with tfap2a in neural crest induction, indicating an early ectodermal patterning role masked by paralog redundancy.\",\n      \"evidence\": \"Single and double antisense morpholino knockdown with transplant cell-autonomy tests in zebrafish embryos\",\n      \"pmids\": [\"17258188\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Single knockdown shows no phenotype, leaving non-redundant functions unresolved\", \"Direct target genes in neural crest not mapped\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Identified TFAP2C as a direct activator of the ERα promoter that drives estrogen-dependent breast cancer growth, defining its role in hormone-responsive tumor biology.\",\n      \"evidence\": \"ChIP, siRNA knockdown, and xenograft assays in breast cancer cells\",\n      \"pmids\": [\"17875680\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not address why binding is restricted to certain cell contexts\", \"Broader target set unknown\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Showed that TFAP2C promoter occupancy is epigenetically gated, explaining context-dependent target activation in ERα-positive versus negative tumors.\",\n      \"evidence\": \"ChIP, methylation analysis, chromatin accessibility assays, and AZA/TSA pharmacologic rescue in breast cancer cells\",\n      \"pmids\": [\"19458056\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism linking methylation to loss of binding affinity not resolved structurally\", \"Generality across other targets initially untested\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Defined the genome-wide TFAP2C binding consensus and primary target set, converting it from a single-gene regulator to a network hub controlling estrogen and growth-factor signaling.\",\n      \"evidence\": \"ChIP-seq plus expression arrays after knockdown in MCF-7 cells\",\n      \"pmids\": [\"20629094\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct versus indirect effects not fully separated for all 447 targets\", \"Cofactor requirements for activation vs repression unaddressed\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Revealed a repressive mechanism in which TFAP2C nucleates a ternary complex with Myc and KDM5B to silence p21 and drive cell-cycle progression, establishing it as a corepressor-recruiting factor as well as an activator.\",\n      \"evidence\": \"Reciprocal co-IP, endogenous ChIP, domain-mapping mutagenesis and cell-cycle readouts\",\n      \"pmids\": [\"22371483\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of the ternary complex unknown\", \"Whether this complex operates at other loci untested\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Expanded the direct target repertoire to GPX1 and the RET proto-oncogene, with GPX1 again gated by CpG methylation, reinforcing the epigenetically controlled, ER-independent regulatory program.\",\n      \"evidence\": \"ChIP-seq, EMSA, luciferase reporters, knockdown and 5-aza-dC rescue in breast cancer cells\",\n      \"pmids\": [\"22964634\", \"22878616\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of each target on tumor phenotype not fully dissected\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Established TFAP2C as essential for primordial germ cell maintenance through direct regulation of germ-cell and DNA-methylation machinery genes, linking it to germline development and teratoma predisposition.\",\n      \"evidence\": \"Conditional knockout mouse, expression profiling, and ChIP at multiple germline target loci\",\n      \"pmids\": [\"23967156\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cofactors directing germline-specific binding not identified\", \"Mechanism of teratoma predisposition incompletely defined\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Showed TFAP2C maintains luminal breast epithelial identity, with loss driving EMT and a basal cell-state shift in vivo, defining its role in epithelial lineage fidelity.\",\n      \"evidence\": \"siRNA knockdown, conditional knockout mammary mouse model, and FACS of mammary populations\",\n      \"pmids\": [\"24469049\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct targets enforcing luminal identity not enumerated here\", \"Reversibility of the state shift untested\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Defined TFAP2C-driven trophoblast and placental development via repression of Cdkn1a and Dusp6 to sustain ERK/AKT signaling, and a parallel role driving EGFR/RET dependency in luminal breast cancer.\",\n      \"evidence\": \"Conditional knockout, signaling Westerns, human trophoblast knockdown, ChIP-seq and dual-knockdown epistasis with xenografts\",\n      \"pmids\": [\"26811378\", \"26832794\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether placental and tumor programs share cofactors unknown\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Established TFAP2C as a pioneer-like enhancer-opening factor for naive pluripotency and germ-cell identity, with a specific OCT4 enhancer required for hPGCLC specification.\",\n      \"evidence\": \"ATAC-seq, ChIP-seq, loss/gain-of-function in human ESCs, and CRISPR enhancer deletion\",\n      \"pmids\": [\"29695788\", \"30590035\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether TFAP2C acts as a true pioneer factor on nucleosomal DNA not directly shown\", \"Recruited remodelers unidentified\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Positioned TFAP2C as the initiating factor in a two-stage epidermal differentiation cascade, sufficient to launch surface-ectoderm fate and induce p63, and identified a non-developmental role in cell-collision guidance via RND3.\",\n      \"evidence\": \"ATAC-seq, ChIP-seq, RNA-seq and gain-of-function in human PSCs; live imaging and actomyosin assays for collision guidance\",\n      \"pmids\": [\"30686763\", \"31659294\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How TFAP2C primes chromatin ahead of p63 mechanistically unresolved\", \"Direct vs indirect control of RND3 not fully separated\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Placed TFAP2C within the germline specification hierarchy downstream of GATA factors and identified its physical association with the Sin3a corepressor component Arid4b, connecting its repressive activity to a defined corepressor complex.\",\n      \"evidence\": \"TF sufficiency and knockout epistasis for hPGCLC induction; endogenous co-IP and PLA for Arid4b interaction\",\n      \"pmids\": [\"33608411\", \"33907498\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Arid4b interaction confidence is Medium and functional link to repression inferred\", \"Direct contacts within the Sin3a complex not mapped\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Defined TFAP2C as a bipotency/bistability activator in totipotent embryos that paradoxically activates both ICM and TE specifiers and, with TEAD4 and Hippo signaling, resolves the first lineage decision.\",\n      \"evidence\": \"uliCUT&RUN-seq, embryo knockout, gain/loss-of-function and Hippo/apical-domain readouts; direct Sox2 promoter binding shown\",\n      \"pmids\": [\"38243114\", \"38789684\", \"40600821\", \"38574734\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How the same factor activates opposing fate programs at distinct loci mechanistically unclear\", \"Cofactor switching between CDX2 and SOX2 partners not fully explained\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Demonstrated TFAP2C is required cell-autonomously for invasive trophoblast function in hemochorial placentation in a strict gene-dosage manner, with biallelic loss prenatally lethal.\",\n      \"evidence\": \"CRISPR global editing and invasive-trophoblast-specific Cre-lox conditional knockout with histology and growth measurements in rat\",\n      \"pmids\": [\"39625795\", \"39554130\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct invasion-program targets not enumerated\", \"Basis of dosage sensitivity unresolved\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Identified an enhancer-suppressive mechanism in which TFAP2C recruits HDAC1 to chromatin to limit enhancer H3K27 acetylation, with SUMO machinery modulating its genome-wide occupancy.\",\n      \"evidence\": \"ChIP-seq under UBA2 and TFAP2C knockdown plus chromatin interactome proteomics (preprint)\",\n      \"pmids\": [\"38645262\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Preprint status warrants caution\", \"Mechanism by which UBA2/SUMO controls TFAP2C binding indirect and undefined\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Extended the HDAC-recruitment model to direct promoter repression of KEAP1, linking TFAP2C to NRF2-dependent antioxidant defense and ferroptosis resistance, consolidating its role as a recurrent suppressor of ferroptosis across cancers.\",\n      \"evidence\": \"ChIP, luciferase, HDAC1/2 recruitment analysis, and ferroptosis/redox assays in ovarian cancer cells\",\n      \"pmids\": [\"41703284\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether KEAP1 repression uses the same Sin3a/HDAC complex as enhancer suppression untested\", \"Generality across the multiple reported ferroptosis-resistance targets not unified\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How a single factor switches between activating and HDAC-mediated repressive outputs at different loci, and what cofactors and chromatin features dictate this choice, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural model of TFAP2C cofactor complexes\", \"Determinants directing activator vs repressor mode at a given target undefined\", \"Pioneer activity on nucleosomal DNA not directly demonstrated\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [2, 3, 5, 27, 45]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 2, 3, 13, 16, 27]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [3, 35, 38]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [2, 3, 27, 35]},\n      {\"term_id\": \"GO:0000228\", \"supporting_discovery_ids\": [13, 16, 35]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 2, 3, 27]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [7, 13, 16, 23, 27, 36, 44]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [13, 16, 35, 38]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [3, 9, 12]},\n      {\"term_id\": \"R-HSA-1474165\", \"supporting_discovery_ids\": [7, 14, 23, 39]}\n    ],\n    \"complexes\": [\"Sin3a corepressor complex (via Arid4b)\", \"TFAP2C-Myc-KDM5B ternary complex\"],\n    \"partners\": [\"MYC\", \"KDM5B\", \"ARID4B\", \"TEAD4\", \"SOX17\", \"CDX2\", \"HDAC1\", \"KLF5\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}